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ABSTRACT 
Positron emission tomography (PET) radiopharmaceuticals are composed of a 
positron emitting radionuclide (e.g. gallium-68) and a molecular structure. 
MicroRNA-21 is a relevant target overexpressed in many diseases, such as 
osteoporosis and osteosarcoma. Interference of microRNA-21 by anti-microRNA-
21 would be a potential medicinal treatment.  
3′-NOTA-chelated anti-microRNA-21 was radiolabeled with gallium-68 using 
the fractionated method and mixed with 5′-alendronate-conjugated microRNA-21. 
68Ga-labeled double helix was formed rapidly at room temperature. The double 
helix thus formed was in vivo PET imaged to evaluate whether its bone 
accumulation was increased because of conjugated bis(phosphonate). PET imaging 
revealed that bis(phosphonate)-conjugated anti-microRNA-21 accumulates in the 
bone. This observation can be utilized in the future when developing medicinal 
treatments for diseases involving micro-RNA-21. 
Sialic acid-binding immunoglobulin-like lectin-9 (Siglec-9) is a leukocyte 
ligand of vascular adhesion protein-1 (VAP-1). VAP-1 plays an important role in 
many inflammatory conditions. Inflammation has s signicifant part in a number of 
diseases, such as atherosclerosis and diabetes. PET imaging provides tools for 
studying the mechanisms related to the process of inflammation and to discover 
potential targeted therapeutics. [68Ga]Ga-DOTA-Siglec-9 can be used as a PET 
tracer for imaging of inflammation.  
The purpose of this thesis was to develop an automated protocol for producing 
GMP-grade inflammation imaging agent [68Ga]Ga-DOTA-Siglec-9 for first-in-
human studies. This GMP-grade tracer was produced using a fully automated 
acetone-based method. It was concluded that this method facilitates efficient 
production of GMP-grade [68Ga]Ga-DOTA-Siglec-9 and the tracer is suitable for 
human use. 
KEYWORDS:  68Ga-radiolabeling, acetone-based method, bis(phosphonate)-
conjugated anti-microRNA-21, fractionated method, Siglec-9 
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TIIVISTELMÄ 
Positroniemissiotomografiassa (PET) käytettävät radiolääkeaineet koostuvat 
positronisäteilevästä radionuklidista (esim. gallium-68) ja molekyylirakenteesta. 
MikroRNA-21 ylierittyy monissa sairauksissa, kuten osteoporoosissa ja osteo-
sarkoomassa. MikroRNA-21-rakenteen estäminen vastinparilla (anti-mikroRNA-
21) on potentiaalinen hoitokeino.  
3′-NOTA-kelatoitu anti-mikroRNA-21 radioleimattiin gallium-68:lla käyttä-
mällä fraktiointimenetelmää ja sekoitettiin 5′-alendronaatti-konjugoidun 
mikroRNA-21:n kanssa. 68Ga-radioleimattu kaksoiskierre muodostui nopeasti 
huoneenlämpötilassa. Rakenne PET-kuvattiin sen arvioimiseksi, lisääkö konjugoi-
minen bisfosfonaattiin sen luuhakuisuutta. PET-kuvantamisen avulla todettiin, että 
bisfosfonaatti-konjugoitu anti-mikroRNA-21-rakenne kerääntyy luustoon. Tätä 
havaintoa voidaan hyödyntää tulevaisuudessa kehitettäessä lääketieteellisiä hoitoja 
sairauksiin, joihin mikroRNA-21-rakenne liittyy.  
Siaalihappoon sitoutuva immunoglobuliinin kaltainen lektiini-9 (Siglec-9) on 
vaskulaarisen adheesiomolekyylin (VAP-1) ligandi. VAP-1:llä on tärkeä osuus 
elimistön tulehdustiloissa. Tulehduksella on merkittävä rooli monissa sairauksissa, 
kuten ateroskleroosissa ja diabeteksessa. PET-kuvantamisen avulla voidaan tutkia 
tulehdusprosessia ja löytää siihen hoitokeinoja. Radiolääkeainetta [68Ga]Ga-
DOTA-Siglec-9 voidaan käyttää tulehduksen PET-kuvantamiseen.  
Väitöskirjan tarkoituksena oli kehittää automaattinen menetelmä tulehduksen 
kuvantamiseen käytettävän GMP-laatuisen [68Ga]Ga-DOTA-Siglec-9 radiolää-
keaineen tuottamiseksi ensimmäisiin kliinisiin tutkimuksiin. Radiolääkeaine 
valmistettiin käyttämällä automaattista asetonipohjaista menetelmää. Menetelmä 
mahdollistaa GMP-laatuisen [68Ga]Ga-DOTA-Siglec-9 radiolääkeaineen tehokkaan 
tuotannon. Radiolääkeaine soveltuu kliiniseen käyttöön. 
AVAINSANAT: 68Ga-radioleimaaminen, asetonipohjainen menetelmä, bisfosfo-
naatti-konjugoitu anti-mikroRNA-21, fraktiointimenetelmä, Siglec-9 
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Abbreviations 
ACN Acetonitrile 
Al2O3 Aluminium oxide 
ASO Antisense oligonucleotide 
BFC Bifunctional chelator 
BPAMD 4-{[(bis-phosphonomethyl)-carbamoyl]methyl}-7,10-
bis(carboxymethyl)-1,4,7,10-tetraazacyclo-dodec-1-yl-acetic 
acid 
BPAPD 4-{[(bis-phosphonopropyl-carbomoyl]methyl}-7,10-bis-
(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl-acetic acid  
BPPED Tetraethyl-10-{[(2,2-bis-phosphonoethyl)hydroxyl-
phosphoryl]methyl}-1,4,7,10-tetraazacyclododecane-1,4,7-
triacetic acid  
11C Carbon-11 
CE Capillary electrophoresis 
cGMP Current Good manufacturing practice 
CT Computed tomography 
Cyclen 1,4,7,10-tetraazacyclododecane  
DATA 6‐amino‐1,4‐diazepinetriacetic acid 
DFO Deferoxamine 
DNA Deoxyribonucleic acid 
DOTA 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid 
DOTA-NOC DOTA-1-NaI3-octreotide 
DOTA-TATE DOTA-Tyr3-octreotate 
DOTA-TOC DOTA-Tyr3-octreotide 
EDTA Ethylenediamine-N,N,N′,N′-tetraacetic acid 
EOS End of synthesis 
EtOH Ethanol 
18F Fluorine-18 
FDA U.S. Food and Drug Administration 
Fe3+ Iron(III) 
FID Flame ionization detector 
67Ga Gallium-67 
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68Ga Gallium-68 
GaCl4 Tetrachlorogallate 
GC Gas chromatography 
Ge Germanium 
GMP Good manufacturing practice 
HBED N,N′-bis(2- hydroxybenzyl)- ethylenediamine-N,N′-diacetic acid 
HBED-CC N,N′-bis[2-hydroxy-5(carboxy-ethyl)benzyl]ethylenediamine-
N,N′-diacetic acid 
HBr Hydrogen bromide 
HCl Hydrochloric acid 
H2dedpa 6,60-(ethane-1,2 diylbis(azanediyl))bis (methylene)dipicolinic 
acid 
HEPES 4-(2-hydroxyethyl)piperazine-1-ethanesulfonic acid  
HNO3 Nitric acid 
H3NOKA 6,6′,6′′-(1,4,7-triazonane-1,4,7-triyl)tris(methylene)tris(5-
hydroxy-2 (hydroxymethyl)-4Hpyran-4-one) 
HPLC High performance liquid chromatography 
HPO 3-hydroxy-4-pyridinone 
H3PO4 Phosphoric acid 
iTLC Instant thin-layer chromatography 
i.v. Intravenously 
LAN Lanreotide 
M Molar 
MicroRNA  miRNA 
MRI Magnetic resonance imaging  
mRNA Messenger RNA  
13N Nitrogen-13 
N Normal 
Na Sodium 
NaCl Sodium chloride 
NaOAc Sodium acetate 
NET Neuroendocrine tumor 
NH4OAc Ammoniumacetate 
NO2AP 1,4,7-triazacyclononane-1,4-diacetic acid 
NOC [NaI3]-octreotide 
NODAGA 1,4,7-triazacyclononane,1-glutaric acid-4,7-acetic acid 
NODAPA-NCS 1,4,7-triazacyclononane-1,4-diacetic acid-7-p-isothio-
cyanatophenyl-acetic acid 
NODAPA-(NCS)2 1,4,7-triazacyclononane-1-acetic acid-4,7-di-p-
isothiocyanatophenyl-acetic acid 
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NODAPA-OH 1,4,7-triazacyclononane-1,4-diacetic acid-7-p-hydroxyphenyl-
acetic acid 
NODASA 1,4,7-triazacyclononane-1-succinic acid-4,7-deacetic acid 
NOTA 1,4,7-triazacyclononane-1,4,7-triacetic acid 
NOTAM 1,4,7-triazacyclononate-1,4,7-triacetamide 
NOTP 1,4,7-triazacyclononane-N,N′,N′′-tris(methylenephos-phonic) 
acid 
NOTPME 1,4,7-triazacyclononane-N,N′,N′′-tris(methylenephosphonate-
monoethylester 
NP-HPLC Normal-phase chromatography 
OSEM3D Ordered-subsets expectation maximization 3D 
PET Positron emission tomography 
Ph. Eur. European Pharmacopoeia 
PP Pyrophosphate 
PSL Photostimulated luminescence 
PSMA Prostate-specific membrane antigen  
QA Quality assurance 
QC Quality control 
RAC Radioactivity concentration 
RCP Radiochemical purity  
RCY Radiochemical yield  
RGD Arg-Gly-Asp  
RNA Ribonucleic acid 
RNAi RNA interference  
ROI Regions of interest 
RP-HPLC Reversed-phase chromatography 
r.t. Room temperature  
SAX Strong anion-exchange 
SCX Strong cation-exchange 
SD Standard deviation 
SG Silica gel 
Siglec Sialic acid-binding immunoglobulin-like lectin 
siRNA Small interfering ribonucleid acid 
SnO2 Tin dioxide 
SOP Standard operating procedure 
SPE Solid phase extraction 
SPECT Single photon emission computed tomography 
SSTR Somatostatin receptor 
SUV Standardized uptake value 
TAC Time-radioactivity curve 
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TACN 1,4,7-triazacyclononane 
TACN-TM 1,4,7-tris(2 mercaptoethyl)-1,4,7-triazacyclononane 
TATE [Tyr3]-octreotate 
TFA Trifluoroacetic acid 
THP Tris(3,4-hydroxypyridinone) 
Ti4+ Titanium(IV) 
TiO2  Titanium dioxide 
TLC Thin-layer chromatography 
TOC [Tyr3]-octreotide 
TRAP Triazacyclononane phosphinic acid 
TRAP-H Triazacyclononane methylphosphinic acid 
TRAP-OH Triazacyclononane methyl- (hydroxymethyl)phosphinic acid 
TRAP-Ph Triazacyclononane methyl(phenyl)phosphinic acid 
UPLC Ultra performance liquid chromatography 
UV Ultraviolet 
VAP-1 Vascular adhesion protein-1 
68Zn Zinc-68 
68Zn(NO3)2 Zinc-68 nitrate 
ZrO2 Zirconium dioxide 
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1 Introduction 
Positron emission tomography (PET) provides quantitative images of biological 
processes in vivo at molecular level. It provides clinically important information for 
tumor diagnosis, cardiovascular diseases, neurological applications (Maisey, 2005) 
and infection and inflammation (Zhuang and Alavi, 2002). PET 
radiopharmaceuticals consist of two components: a molecular structure (ligand, 
vector, vehicle) and a positron emitting radionuclide. In order to make a stable 
connection between these two parts, a linker may be chemically necessary. The 
molecular structure defines the biological characteristics. It is responsible for 
biochemical and chemical interactions within the living organism and it has to 
provide a high degree of selectivity and specificity towards the target site. These 
targets can be e.g. antigens or selected receptor systems. The molecular structure 
either takes part directly in the metabolic processes or interacts with the targets. 
(Wadsak and Mitterhauser, 2010, Boschi et al., 2013) 
The most common radionuclides for PET radiopharmaceuticals include carbon-
11 (11C, t½ = 20 minutes), nitrogen-13 (13N, t½ = 10 minutes), oxygen-15 (15O, t½ = 
123 seconds), fluorine-18 (18F, t½ = 110 minutes), gallium-68 (68Ga, t½ = 68 
minutes) and rubidium-82 (82Rb, t½ = 78 seconds). Radiometals, such as 68Ga, can 
only be fixed to the molecular structure using a metal-ligand-complex. 
Radionuclides can be produced using cyclotrons and generators. 68Ga is one of the 
very early radionuclides applied to PET imaging at a time when not even the 
wording PET itself was yet established and a long time before the usage of, for 
example, 18F. (Tsang et al., 1993, Wadsak and Mitterhauser, 2010, Boschi et al., 
2013, Rösch, 2013, Huang, 2018) 
68Ga-based imaging agents comprising small molecules, large biomolecules 
and particles have been explored for the imaging and quantitation of various 
physiological disorders and biological functions. The molecular imaging of 
oncological diseases has been investigated most extensively for targeting receptors, 
enzymes and antigens. In addition, visualization of downstream biological 
processes, such as angiogenesis, apoptosis, hypoxia, glycolysis and proliferation, 
has also been performed. Probes for non-targeted imaging of pulmonary and 
Introduction 
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myocardial perfusion and ventilation as well as targeted imaging of inflammation, 
infection and messenger RNA (mRNA) have also been studied. (Velikyan, 2014) 
In general, the production of 68Ga-labeled radiopharmaceuticals involves 
elution of the generator, pre-purification of the eluate, the heating step, purification 
of the crude product and formulation of the injection solution. Buffer solutions are 
used to adjust the optimal reaction mixture pH as necessary for the chelate 
complexation. Recently, the use of fully automated systems for the production of 
68Ga-radiopharmaceuticals has increased. (Boschi et al., 2013)  
The purpose of quality control (QC) of PET radiopharmaceuticals is to assure 
the safety of the product before its release for clinical use. QC involves several 
specific tests and measurements to ensure product purity, identity, efficacy and 
biological safety (Ha et al., 2017). Product purity consists of radionuclidic purity 
and chemical purity. Radionuclidic impurities can impact the quality of PET 
images. Chemical purity concerns solvents, by-products and other residual 
components used during the production. All of them can affect radiolabeling 
negatively. High performance liquid chromatography (HPLC) and thin-layer 
chromatography (TLC) are commonly used chromatographic methods in the QC of 
68Ga-radiopharmaceuticals.  
Several peptide analogues of vascular adhesion protein-1 (VAP-1) ligands have 
been designed for visualization of VAP-1 expressed on endothelial surface in 
infection and inflammation (Velikyan, 2014). Linear 9-amino acid DOTA-chelated 
peptide targeting VAP-1 ([68Ga]Ga-DOTAVAP-P1) and its modifications have 
been introduced and radiolabeled with 68Ga in order to study their stability and 
potential to function as a PET tracer and to demonstrate specific binding and 
capability to differentiate between inflammation and infection using animal models 
(Lankinen et al., 2008, Ujula et al., 2009, Silvola et al., 2010, Aalto et al., 2011, 
Autio et al., 2011, Ahtinen et al., 2014, Virtanen et al., 2015, Virtanen et al., 2017). 
One of them is the cyclic peptide CARLSLSWRGLTLCPSK (containing residues 
283–297 from sialic acid-binding immunoglobulin-like lectin-9 (Siglec-9)) bearing 
1,4,7,10-tetraazacyclo-dodecane-1,4,7,10-tetraacetic acid (DOTA) chelator. 
Chemical derivatization of small interfering ribonucleic acid (siRNA) and 
antisense oligonucleotides (ASO) has continued exhaustively over the past decades 
(Yamamoto et al., 2011, Winkler, 2013). Different modifications have been 
prepared and many of them have been evaluated for therapeutic use. There are 
many challenges related to the therapeutic application of nucleic acid-derived 
compounds. Delivery to tissues and organs other than the liver has not been 
achieved in a satisfactory manner yet. For example, it has been observed in some 
cases that oligonucleotides are rapidly eliminated by renal filtration, thus 
demanding high doses. (Winkler, 2013) 
Meeri Käkelä 
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Good manufacturing practice (GMP) is one aspect of quality assurance for 
ensuring that medicinal products are consistently produced and controlled 
according to the relevant quality standards as required by the product 
specifications. The purpose is to minimize the risks involved in pharmaceutical 
production that cannot be eliminated through testing the final product. GMP covers 
all aspects of medicinal production including equipment, starting materials, 
premises and training of staff. It is highly important to have systems capable of 
providing documented proof that correct procedures are followed during the 
manufacturing processes.  
The production of PET radiopharmaceuticals must be in compliance with the 
basic principles of GMP. The fact that PET radiopharmaceuticals are short-lived 
radiopharmaceuticals brings challenges to QC. The short half-life means that PET 
radiopharmaceuticals must be released and administered to a patient immediately 
after their production. The produced batch is authorized for clinical use before 
completion of all tests and the final release is approved later on (the two-stage 
release). (World Health Organization, 2003, Poli et al., 2014)  
In the research project for this thesis, GMP-grade and nonGMP-grade 68Ga-
labeled DOTA-Siglec-9 peptide and nonGMP-grade 3′-[68Ga]Ga-NOTA-anti-
microRNA-21 were produced and their QC was carried out using radio-HPLC 
and/or radio-TLC. In vitro stability and plasma protein binding of these potential 
PET tracers were determined using radio-HPLC. In addition, the in vivo stability 
and bone accumulation of 68Ga-labeled oligoribonucleotide were determined using 
PET and biodistribution measurements with gamma counter. The research project 
consists of three subprojects in which radiolabeling protocols for GMP-grade 
[68Ga]Ga-DOTA-Siglec-9 and nonGMP-grade 3′-[68Ga]Ga-NOTA-anti-
microRNA-21 are being developed and the feasibility of these tracers as PET 
tracers is studied with animal experiments.  
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2 Review of the Literature 
2.1 Radiochemistry 
Over one hundred years ago Henri Becquerel discovered the phenomenon of 
radioactivity (Myasoedov, 2000). The radiotracer technique developed by George 
(György) de Hevesy in 1924 is the basis of nuclear medicine. The principle of the 
technique is that changing an atom in a molecule for its radioisotope will not 
significantly change its biological and chemical behavior, while the distribution, 
movement and concentration of the molecule and its derivatives can be followed by 
measuring its radiation. Also, processes in a live animal or human can be studied 
using external radiation detectors. Modern devices allow for the detection of so 
small amounts (in terms of molarity) of the tracer that the function of the studied 
organ is not affected. (Varga, 2012) 
Radiochemistry is the science that encompasses the production, separation and 
purification of radionuclides. In addition, it includes the synthesis of radiolabeled 
compounds for biological or biochemical research. Radiochemical reactions are 
performed using very small amounts of the radionuclides. Accordingly, there are 
practical considerations, such as the risk of having a significant proportion of a 
radionuclide sample adsorbed onto the reaction glassware. The successful 
application of radiochemical techniques requires careful attention to all details and 
plenty of practice. Nowadays, novel applications within medicine and biology for 
the purposes of diagnostics, study of biomechanical processes, environmental 
science, and element speciation and migration are being increasingly discovered. 
(Myasoedov, 2000, Ebenhan et al., 2017) 
2.1.1 Radioisotopes of gallium 
Gallium (Ga) has two natural stable isotopes, namely 69Ga (60%) and 71Ga (40%). 
Gamma camera imaging to image lymphoma using the longest-lived radioisotope 
of Ga, gallium-67 (67Ga, t½ = 78 hours), has been employed regularly in the clinic 
since the 1980s. Besides of its gamma emissions for single photon emission 
computed tomography (SPECT) imaging and scintigraphy, 67Ga also emits Auger 
electrons. Thus, it has potential as a therapeutic radionuclide. Two isotopes, 
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gallium-66 (66Ga, t½ = 9.5 hours) and 68Ga (t½ = 68 minutes), are suitable for PET 
imaging. 68Ga (Q+ = 2.92 MeV; Emax = 1.89 MeV) decays to 88.91% by positron 
emission and to 11.09% via electron capture into stable zinc-68 (68Zn). The average 
positron energy per disintegration is 829.5 keV. (Banerjee and Pomper, 2013, bin 
Othman et al., 2017, Boschi and Lodi, 2017, Ebenhan et al., 2017, Tsionou et al., 
2017)  
The physical half-life of 68Ga is compatible with the pharmacokinetics of many 
PET radiopharmaceuticals of low molecular weight, such as peptides, 
oligonucleotides, antibody fragments and aptamers (Boschi and Lodi, 2017). 68Ga 
has demonstrated its feasibility for the radiolabeling of biological macromolecules, 
small compounds and micro- and nano-particles (Velikyan, 2011). The major 
application domain is oncology. Potential has been demonstrated for imaging of 
inflammation and infection as well as lung ventilation, pulmonary perfusion and 
myocardial perfusion. Imaging of general biologic properties and processes, such 
as angiogenesis, apoptosis, glycolysis, hypoxia and proliferation, has also been 
investigated. (Velikyan, 2011, Velikyan, 2014) 
Ga can form four-, five- and six-coordinated complexes. Six-coordinated 
complexes are the most stable with an octahedral coordination sphere. Ga is 
suitable for complexation with polydentate ligands, both cyclic and open chain 
structures. The majority of ligands designed for Ga are hexadentate. The Ga3+ ion 
is classified as a hard Lewis acid, forming thermodynamically stable complexes 
with ligands that are hard Lewis bases containing oxygen, nitrogen and sulfur 
donor atoms, such as carboxylate, phosphonate, amine and hydroxamate. Softer 
functional groups, such as phenolate and thiol groups, have also been found to be 
appropriate. The ligand is called a bifunctional chelator (BFC) if it binds the metal 
cation and also presents a functionality, often an amino group or a carboxyl group, 
that allows covalent coupling to a targeting vector. The principal requirements are 
that ligands should form stable complexes with Ga preferably of octahedral 
geometry in order to yield stable complexes. (Maecke and André, 2007, Velikyan, 
2011, Velikyan, 2014, Boschi and Lodi, 2017) 
  
Review of the Literature 
19 
11C is bound covalently within the vehicle molecule. 18F is also attached 
covalently to the parent molecule but it has to be added to the original structure. 
68Ga and other radiometals can 
only be fixed to the vehicle by 
using a metal-ligand-complex. 
Metal-ligand interactions within 
a complex are usually much 
weaker than a covalent binding. 
Metal-ligand-complex leads to 
significant changes in the 
electronical and steric 
configuration. It also changes 
the pharmacodynamics and 
pharmacokinetics of the 
radiopharmaceutical. (Wadsak 
and Mitterhauser, 2010) 
Figure 1. A schematic view of a 68Ge/68Ga generator. 
(Costello et al., 2015) 
2.1.2 68Ge/68Ga generators and cyclotrons 
Radionuclide 68Ga can be produced using a cyclotron (Pandey et al., 2014, Alves et 
al., 2017, Riga et al., 2018) or a cost-effective 68Ge/68Ga generator, which is simple 
in use. Pandey and co-workers have developed an automated system for the 
separation of 68Ga from 68Zn nitrate (68Zn(NO3)2). They performed 30-minutes 
irradiations with 1.7 molar (M) solutions of 68Zn(NO3)2 (99.23% isotopic 
enrichment) in 0.2 normal (N) nitric acid (HNO3). They concluded that the 
enhanced heat transfer allowed irradiation as a closed system. They also pointed 
out that 68Ga can be produced on a low energy cyclotron in sufficient quantities to 
provide an alternative to 68Ge/68Ga generators. Riga and co-workers also showed 
that 68Zn(p,n)68Ga nuclear reaction is feasible for the production of 68Ga using 
medicinal cyclotron. This is an economical alternative to 68Ge/68Ga generators. It 
has been proved that the quality of cyclotron-produced 68Ga is equal or even better 
when compared with the generator-produced 68Ga. (Pandey et al., 2014, Lin et al., 
2018, Riga et al., 2018) 
Current 68Ge/68Ga generators can nominally deliver up to 1.85 GBq (50 mCi) 
of 68Ga per elution. However, 68Ga activity decreases over time due to the decay of 
the parent nuclide germanium-68 (68Ge). It decays spontaneously with a half-life of 
271 days by electron capture. Unfortunately, elution efficiencies around 80% of 
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present activity are typical. Thus, cyclotrons show potential for large scale 
production of 68Ga-radiolabeled tracers. (Lin et al., 2018) 
Radionuclide generators have the advantage of providing radionuclides on 
demand. The parent nuclide of 68Ga is 68Ge, which is produced with an accelerator 
on a gallium oxide target. 68Ge is adsorbed on a stationary material inside the 
generator (Figure 1.). For GMP use, this enables a shelf-life of the generator of up 
to a year. Generators provide on-site access to a GMP-grade diagnostic PET 
radionuclide without the need for cyclotron facilities. (Maecke and André, 2007, 
Fani et al., 2008, Ebenhan et al., 2017, Tsionou et al., 2017) 
From the historical point of view, the availability of 68Ga as a PET radionuclide 
goes back to the time when 18F-tracers were not yet established. The first 68Ge/68Ga 
generator, the so-called positron cow, was developed in 1960. The separation of 
68Ge was accomplished by distillation of volatile germanium tetrachloride, the 
distillate was extracted with carbon tetrachloride and the activity returned to an 
aqueous phase. Separation of the radionuclides was done utilizing anion-exchange 
procedures. Acetylacetone was used to extract the carrier-free activity from the 
acid solution of 68Ge. It was observed that it is possible to return the product to an 
aqueous phase of 0.1 M hydrochloric acid (HCl). Finally, the injectable preparation 
was made. (Gleason, 1960, Ebenhan et al., 2017) 
An improved generator version was introduced in 1961. It employed an 
aluminium oxide (Al2O3)-based column matrix. 68Ga was eluted with a sodium 
ethylenediamine-N,N,N′,N′-tetraacetic acid (Na-EDTA) solution. The next 
generation of generators was launched in 1974. This made it possible that 68Ga 
could be eluted directly in an ionic form. The new generator type also set the 
design of today’s commercially available generators. Despite growing clinical use, 
especially in Europe, the first commercial generator has received marketing 
authorization as recently as 2014. (Greene and Tucker, 1961, Kopecký and 
Mudrová, 1974, Blower, 2016, Ebenhan et al., 2017) 
Due to the long half-life of 68Ge, a good separation system of mother and 
daughter nuclides is mandatory to avoid breakthrough (Maecke and André, 2007, 
Fani et al., 2008). The current generators are modified on metal oxides, such as 
titanium dioxide (TiO2), tin dioxide (SnO2) and Al2O3. In addition, inorganic 
supports (silica-based) and organic polymer resins are used. Macroporous organic 
polymer based on N-methylglucamine has shown to be suitable as an organic 
matrix (Nakayama et al., 2002). Pyrogallol-formaldehyde polymer resins allow for 
the elution of 68Ga as tetrachlorogallate anion (68GaCl4−) with 5.5 M HCl followed 
by purification from low levels of breakthrough 68Ge and concentration by 
adsorption on a small Dowex anion-exchange column as 68GaCl4−. It is then eluted 
with water to afford a concentrated solution of 68Ga3+ in 0.5 M HCl. This type of a 
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generator shows a very low breakthrough. (Schuhmacher and Maier-Borst, 1981, 
Zhernosekov et al., 2007, Ebenhan et al., 2017) 
Inorganic matrices were the first to be used for efficient separation. Inorganic 
ion-exchangers have a high radiolytic stability (Pillay, 1986). Al2O3 or zirconium 
dioxide (ZrO2) was used and 68Ga was eluted as [68Ga]Ga-EDTA-complex, which 
must be destroyed before the radionuclide can be incorporated into the required 
PET radiopharmaceutical. This made every synthesis of a radiopharmaceutical 
tedious and time-consuming. After replacing Al2O3 by antimony pentoxide and 
EDTA by sodium oxalate solution, the elution yield was more stable (Arino et al., 
1978). To make the process simpler, attempts were focused on the development of 
generators that provide 68Ga3+ free from any complexing agent. Several systems 
were proposed, such as Al2O3, ferric hydroxide, HCl, HNO3, silicon dioxide and 
ZrO2 (Kopecký and Mudrová, 1974, Neirinckx and Davis, 1979). A new type of 
68Ge/68Ga generators based on HCl elution provides ionic 68Ga3+ instead of 68Ga-
complexes. These became commercially available in the early 2000s (Razbash et 
al., 2005). This development has offered new opportunities for PET 
radiopharmaceutical chemistry based on trivalent metals. (Greene and Tucker, 
1961, Maecke and André, 2007, Fani et al., 2008, Rösch, 2013, Ebenhan et al., 
2017) 
Nowadays, a commonly used commercially available 68Ge/68Ga generator is 
based on a TiO2-solid support. 68Ga can be conveniently eluted with up to 10 mL 
diluted HCl as soluble 68Ga3+. SnO2 is another common column packing material in 
modern 68Ge/68Ga generators. 68Ga is eluted as 68Ga3+ with HCl while 68Ge, form 
68Ge4+, remains adsorbed. For fresh generators, 68Ga-eluate yield ranges from 70% 
to 80%. 68Ge-breakthrough is at levels of about 0.01–0.001%, or even better for 
fresh generators, increasing over longer periods of generator usage. (Rösch, 2013, 
Ebenhan et al., 2017) 
Nano-zirconia has been studied as a sorbent for the preparation of the 68Ge/68Ga 
generator. The results have proved that a major advantage of this kind of a 
generator is its consistency, which is superior to that of the SnO2- and TiO2-based 
68Ge/68Ga generators. The major benefits of the nano-zirconia sorbent are proposed 
to be, for example, its rigidity, which allows the use of high flow rates, and the 
chemical and radiation stability of the sorbent matrix. The results have also shown 
that the obtained 68Ga is suitable for preparation of 68Ga-labeled PET 
radiopharmaceuticals with high labeling yield. These generators are suggested 
feasible as an option for use in institutions where commercial sources of PET 
radioisotopes are not readily available. (Chakravarty et al., 2011) 
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2.2 68Ga-labeled PET radiopharmaceuticals and 
their development 
The most widely utilized 68Ga-labeled PET radiopharmaceuticals consist of 68Ga 
coordinated to a chelator that is attached to a peptide, or other molecules, for 
targeting cell surface receptors of tumors (Tsionou et al., 2017). The kinetic and 
thermodynamic stability, geometry and lipophilicity of a chelator-metal ion 
complex are important parameters in the development of radiometal-based PET 
radiopharmaceuticals. These design principles are valid for the 68Ga-labeling of 
biological macromolecules, small biologically active organic molecules, and 
complexes of variable charge, lipophilicity and particles. This means that the 
chemistry considered in the development of 68Ga-based imaging agents has several 
cornerstones, including the coordination chemistry and aqueous chemistry of 68Ga, 
bioconjugate chemistry and design of mono-chelators and BFCs. Nowadays, the 
biodistribution of 68Ga imaging agents is defined by the vector molecule, and 68Ga 
may or may not influence biodistribution or affinity to the target. (Velikyan, 2014) 
Efficient and quantitative radiolabeling allowing the preparation of PET 
radiopharmaceuticals without the need of additional purification further simplifies 
translation of new tracers into clinical practice. Another critical step for clinical 
translation is the selection of the BFC to adjust the polarity and charge of the 
overall conjugate as a means to optimize the route of clearance and the 
pharmacokinetics. For example, the blood clearance of a PET radiopharmaceutical 
should be sufficiently long to facilitate optimal delivery to the target site but also 
short enough to avoid unnecessary radiation exposure. For the design of BFCs of 
high in vivo stability, efficient radiolabeling kinetics and favorable 
pharmacokinetics, a thorough understanding of the coordination chemistry of the 
radiometal of interest is thus essential. (Bartholomä, 2012) 
Great advances in automation technology for 68Ga-radiochemistry and 
radiopharmacy have been achieved lately. Different automation strategies are now 
available and they can also be tailored to different needs. Automation technologies 
have implemented different pre-purification approaches which has led to increased 
radionuclidic and chemical purity as well as high molar activity of the final 
preparation. The use of automated systems has many advantages like easier 
handling, improved reproducibility, higher throughput, improved response to 
clinical demand, and production in compliance with current Good manufacturing 
practice (cGMP). (Boschi et al., 2013) 
Pre-loaded cassette-based modules, manufactured under cGMP standards, have 
already represented an improvement in terms of safety and compliance with 
regulations. In the future, microfluidic approaches could open interesting 
perspectives. Major concerns include radiolysis due to the high concentration of 
radionuclide and surface effects. It has been proposed that development of 68Ga-
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radiopharmaceuticals as freeze-dried kits may be an alternative to cyclotron-based 
PET radiopharmaceuticals. (Boschi et al., 2013) 
2.2.1 Bifunctional chelators 
The biological fate of PET radiopharmaceuticals is determined by the BFC-metal 
complex, the biological properties of the targeting vector and the tether. The choice 
of BFC is determined by the nature and oxidation state of the metallic radionuclide. 
It has been shown that the nature of a BFC-metal complex (lipophilicity, geometry 
and overall charge) plays a crucial role in determining the biodistribution of 
targeted PET radiopharmaceuticals. Chelators of high lipophilicity are not very 
optimal because of their increased uptake in non-target tissues, such as the liver. 
(Bartholomä, 2012) 
The BFC should chelate the radiometal, such as copper, gallium, indium, 
yttrium or zirconium, rapidly and sufficiently when linked to a macromolecule. 
The chelator should be kinetically stable to demetallation over a pH range of 4–8 
and stable in the presence of other serum cations (calcium ion, magnesium ion, 
Zn2+). The BFC should be characterized by high radiolabeling efficiency to yield 
PET radiopharmaceuticals of high molar activity. The receptor population in the 
diseased organ or tissues is often limited in numbers and low molar activity may 
result in blockage of the receptor by the unlabeled bioconjugate and impact the 
efficacy of radiotherapeutics or the image quality. The main objective in the design 
of metal-based PET radiopharmaceuticals is to select an efficient bifunctional 
chelating system that forms the radiometal chelator with kinetic inertness and very 
high thermodynamic stability. This way it is possible to retain the label on the 
targeting vector and to minimize accumulation of the radiometal in non-target 
tissues. In addition, it is possible to optimize image contrast and minimize the 
radiation burden to patients, which is of particular importance for radiotherapeutic 
applications. (Bartholomä, 2012, Boschi and Lodi, 2017)  
The use of radiometals for the labeling of biomolecules generally requires the 
use of BFCs. The BFC is covalently attached to the targeting biomolecule either 
directly or through a linker. These chelators bind the metal at one terminus and 
contain a functional group for the covalent linkage to a targeting vector at the 
second terminus. In an optimal situation, the BFC is able to form a stable 
radiometal chelator with high thermodynamic stability and kinetic inertness. The 
optimal BFC should ideally fulfill several requirements. One requirement is 
stability, meaning that the BFC should form kinetically inert and 
thermodynamically stable complexes to prevent hydrolysis or any ligand exchange 
reactions in vivo. A second requirement is rapid complexation kinetics meaning 
that radiolabeling of the BFC should be efficient and rapid at low temperatures and 
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low concentration at a pH that is suitable for biological targeting vectors. A third 
requirement is that the BFC should selectively bind the radiometal of interest 
because it is important to avoid low molar activity during radiolabeling. Low molar 
activity might be observed due to the presence of other trace metals (decay 
products). A fourth requirement is that BFCs should have versatile conjugation 
chemistry. This means flexibility in the conjugation of the BFC to functional 
groups of targeting vectors. Flexibility allows optimization of pharmacokinetics by 
adjusting the polarity of the overall conjugate. A fifth requirement is accessibility, 
meaning that the preparation of the BFC should be quick, straightforward and cost-
effective. The preparation of BFC should be scalable to the preparation of 
multigram quantities of product with only few reaction steps. (Yang et al., 2008, 
Bartholomä, 2012) 
The two most important parameters of a BFC that influence the in vivo 
properties of PET radiopharmaceuticals are the overall charge and the lipophilicity 
of the corresponding BFC-metal complex. The success of a BFC is not guaranteed 
even when all of the abovementioned requirements are completely fulfilled. This is 
due to the fact that the nature of a BFC can have a profound impact on the 
pharmacokinetics of a PET radiopharmaceutical such as receptor binding and 
clearance from non-target tissues. (Bartholomä, 2012) 
The main requirement for a 68Ga-BFC is the kinetic inertness towards 
transferrin (the blood serum protein transporting iron) and higher thermodynamic 
stability than that of the 68Ga-transferrin complex to avoid any premature ligand 
exchange in vivo during the course of the clinical application. Chelators that 
quantitatively coordinate 68Ga at room temperature (r.t.), near neutral pH and low 
concentrations of chelator-bioconjugate will facilitate one-step, kit-based 
radiolabeling protocols. Such chelators would also be useful for radiolabeling of 
small proteins. However, they are susceptible to degradation or unfolding at 
extremes of pH and temperature. BFCs generally fall into one of two broad 
categories: macrocyclic or acyclic chelators. (Bartholomä, 2012, Charron et al., 
2016, Tsionou et al., 2017) 
2.2.1.1 Macrocyclic chelators 
Macrocyclic chelators are rigid chemical structures designed to ensure that the 
donor atoms are in the optimal location for metal chelation. Macrocyclic ligands 
are the most widely used chelator type for 68Ga. This is due to the generally simple 
synthesis from inexpensive starting materials. In addition, they are also very 
broadly used for PET metal-ion chelation, as well as components of single SPECT 
radiopharmaceuticals and magnetic resonance imaging (MRI) contrast agents. 
(Burke et al., 2014, Charron et al., 2016) 
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The focus in this area is on the development of novel chelators to overcome the 
problem related to the high temperature routinely needed for macrocyclic 68Ga-
complex formation, which is not suitable for many biomolecules. In recent years, 
the design of BFCs in general and for 68Ga-chelators, in particular, has mainly 
focused on ligands based on polyaza-macrocycles, such as 1,4,7,10-
tetraazacyclododecane (cyclen) and 1,4,7-triazacyclononane (TACN). This is 
because of the higher kinetic inertness of macrocycles, as compared with acyclic 
ligands, due to the macrocyclic effect that minimizes transchelation or loss of metal 
in vivo, which is favorable for PET radiopharmaceutical applications. (Bartholomä, 
2012, Burke et al., 2014)  
2.2.1.1.1 Examples of macrocyclic chelators 
Several multidentate cyclen and TACN derivatives with additional donor groups 
have been developed to saturate all coordination sites on the six-coordinate Ga3+. 
The most prominent representative of this category is the aminocarboxylate 
macrocycle ligand DOTA (Figure 2.). DOTA chelator is the current “gold 
standard” bifunctional 68Ga-chelator (Berry et al., 2011). The metal center in the 
[68Ga]Ga-DOTA complex is encapsulated by a N4O2 donor set of the cyclen moiety 
and two carboxylate groups in a cis-pseudooctahedral fashion according to the 
crystal structures of [68Ga]Ga-DOTA and [68Ga]Ga-DOTA-D-PheNH2 (Heppeler et 
al., 1999, Viola et al., 2006). The third carboxylic acid group is deprotonated and 
does not coordinate to the metal. The fourth carboxylic acid function is either 
conjugated to the amino acid via the amide in [68Ga]Ga-DOTA-D-PheNH2 or is not 
involved in metal coordination in [68Ga]Ga-DOTA. (Heppeler et al., 1999, Viola et 
al., 2006, Bartholomä, 2012)   
DOTA has proven to be a very suitable chelator for a number of trivalent metal 
cations. It can be attached to various somatostatin analogues, such as [Tyr3]-
octreotide (TOC), [Tyr3]-octreotate (TATE), [NaI3]-octreotide (NOC), lanreotide 
(LAN) and other peptides, without loss of receptor specificity or binding affinity. 
However, DOTA has several drawbacks as a 68Ga chelator (Berry et al., 2011). Due 
to the kinetic inertness of the macrocycle, the kinetics of complex formation of 
DOTA is slow (Bartholomä, 2012). Several chelators have been evaluated and 
developed for 68Ga-labeling of biomolecules to avoid the limitations of DOTA. 
(Meyer et al., 2004, Petrik et al., 2011, Tsionou et al., 2017) 
TACN-based chelators, such as 1,4,7-triazacyclononane-1,4,7-triacetic acid 
(NOTA), (Figure 2.) show favorable characteristics for 68Ga-radiolabeling. NOTA 
has proven interesting because of its fast and high in vivo stability and reaction 
kinetics, efficient radiolabeling at r.t. and high selectivity towards 68Ga due to 
cavity size. Ga3+ forms thermodynamically less stable complexes with DOTA-like 
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than with NOTA-like chelators (Clarke and Martell, 1991, Kubíček et al., 2010). 
This is a consequence of the excellent fit of the small Ga3+ into the cavity of the 
nine-membered triazamacrocycle of NOTA. Among the macrocyclic chelators, the 
triazacyclononanes display high conformational and size selectivity towards 68Ga 
due to the smaller dimensions of the corresponding cavity in comparison with 
DOTA. (Velikyan et al., 2008, Bartholomä, 2012, Burke et al., 2014)  
A macrocyclic chelator, 6,6′,6′′-(1,4,7-triazonane-1,4,7-
triyl)tris(methylene)tris(5-hydroxy-2 (hydroxymethyl)-4Hpyran-4-one) (H3NOKA) 
(Figure 2.) with pendant 3-hydroxy-4-pyrone arms, is also based on TACN. 
Solution and solid state analyses have revealed that this chelator acts as a 
hexadentate ligand with all six donors (three amine-N atoms and three enolate-O 
atoms) bonding to the metal center. It has been suggested that NOKA-derivatives 
might be useful as bifunctional chelators for 68Ga-labeling of small biomolecules. 
(Yang et al., 2008) 
Three triazacyclononane phosphinic acid (TRAP) (Figure 2.) ligands bearing 
methylphosphinic (TRAP-H), methyl(phenyl)phosphinic (TRAP-Ph) or methyl-
(hydroxymethyl)phosphinic acid (TRAP-OH) pendant arms have been investigated 
as members of a new family of efficient 68Ga-chelators. All of them are TACN-
derivatives. The results have proved that all these are suitable alternatives for the 
development of 68Ga-radiopharmaceuticals. As compared with common DOTA-
derivatives, they show fast complexation of 68Ga3+ over a broad pH range. All these 
complexes are kinetically inert in both acidic and alkaline solutions. Complex 
formation studies in acidic solutions indicate that 68Ga-complexes of the 
phosphinate ligands are formed quantitatively and quickly, in minutes, even at pH 
below 2. (Šimeček et al., 2012, Notni et al., 2014) 
Several derivatives of NOTA (Figure 2.) have been developed and investigated. 
Among these are examples of hexadentate ligands 1,4,7-triazacyclononane-1-
succinic acid-4,7-deacetic acid (NODASA) (Andre et al., 1998), 1,4,7-
triazacyclononane-N,N′,N′′-tris(methylenephosphonic) acid (NOTP), which is a 
phosphonate analog of NOTA (Prata et al., 2000, Fellner et al., 2011), 1,4,7-
triazacyclononane-N,N′,N′′-tris(methylenephosphonate-monoethylester) 
(NOTPME) (Prata et al., 1999) and 1,4,7-tris(2 mercaptoethyl)-1,4,7-
triazacyclononane (TACN-TM) (Ma et al., 1995). All these have demonstrated 
octahedral coordination geometry, high thermodynamic stability and identical 
plasma and in vivo stability. (Velikyan et al., 2008) 
One example of the bifunctional modifications of NOTA is a macrocyclic 
chelator 1,4,7-triazacyclononane,1-glutaric acid-4,7-acetic acid (NODAGA) 
(Figure 2.). NODAGA has three carboxyl groups for coordination with 68Ga after 
conjugation with peptide. It is known to form highly stable complexes with 68Ga. 
Higher target to background ratios have been reported with NODAGA-derivatized 
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peptides in direct comparison with their DOTA counterparts, which is related to 
lower plasma protein binding of the 68Ga-labeled peptide. (Fani et al., 2008, 
Decristoforo et al., 2012, Satpati et al., 2018) 
Other bifunctional NOTA-derivatives include 1,4,7-triazacyclononane-1,4-
diacetic acid-7-p-hydroxyphenyl-acetic acid (NODAPA-OH), 1,4,7-
triazacyclononane-1,4-diacetic acid-7-p-isothio-cyanatophenyl-acetic acid 
(NODAPA-NCS) (Figure 2.) and 1,4,7-triazacyclononane-1-acetic acid-4,7-di-p-
isothiocyanatophenyl-acetic acid (NODAPA-(NCS)2) (Riss et al., 2008). All these 
derivatives show comparable radiolabeling efficiency comparable to that of NOTA. 
It has been reported that, at pH 2.8, up to 85% of these derivatives are radiolabeled 
within three minutes, at 45°C for NODAPA-OH and at 75°C for NODAPA-(NCS)n 
(n = 1–2). The stability of the corresponding 68Ga-complexes is in a similar range 
as that of the congener NOTA. (Bartholomä, 2012) 
2.2.1.2 Acyclic chelators 
The macrocyclic effect generally results in kinetically more inert and 
thermodynamically more stable metal complexes of macrocyclic chelators in 
comparison with the acyclic ones. Thus, BFCs based on macrocycles are more 
attractive for radiopharmaceutical applications. However, a number of acyclic 
chelators have been described that perform quite successfully in vivo. A significant 
advantage of acyclic chelators, especially in the case of shorter-lived radiometals 
such as 68Ga, is the faster metal binding kinetics as compared with macrocyclic 
complexes of corresponding stability, thus resulting in faster radiolabeling. 
(Bartholomä, 2012, Charron et al., 2016) 
Acyclic chelators undergo a conformational change to effectively place the 
donor atoms in the ideal geometry for chelation. Acyclic chelators for 68Ga offer 
great potential due to the fast kinetics involved in the complex formation. Recent 
work in the area has focused on the design of novel chelators, which retain the 
kinetic advantages whilst addressing the issue of low in vivo stability. (Burke et al., 
2014, Charron et al., 2016) 
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Figure 2.  Examples of 68Ga-chelated macrocyclic chelators. 
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2.2.1.2.1 Examples of acyclic chelators 
The acyclic ligand N,N′-bis(2-hydroxybenzyl)ethylenediamine-N,N′-diacetic acid 
(HBED) (Figure 3.) is based on an EDTA-type framework with two pendant 
phenol arms. It has received attention for the design of BFCs for PET 
radiopharmaceutical applications. The acyclic bifunctional ligand N,N′-bis[2-
hydroxy-5(carboxyethyl)benzyl]ethylenediamine-N,N′-diacetic acid (HBED-CC) 
(Figure 3.) is characterized by efficient and rapid radiolabeling at r.t. and high in 
vivo stability. It has been employed for 68Ga-labeling of thermo-sensitive 
biomolecules (Eder et al. 2008). 
Deferoxamine (DFO) (Figure 3.) forms 68Ga-complexes of high 
thermodynamic stability. Its usefulness as a BFC for 68Ga-radioisotopes has been 
proved in combination with peptides and small molecules. It has been observed 
that the labeling of DFO with 68Ga3+ is pH dependent. [68Ga]Ga-DFO-folate has 
been prepared with high radiochemical purity (RCP) (Mathias et al. 2003). DFO-
octreotide has also been 68Ga-labeled successfully. However, [68Ga]Ga-DFO-
octreotide suffers considerable radiation damage when left in the labeling buffer 
for prolonged periods of time (Smith-Jones et al. 1994, Bartholomä 2012). 
Hexadentate tris(3,4-hydroxypyridinone) (THP) (Figure 3.) chelators have high 
affinity for oxophilic trivalent metal ions. This has led to their development for 
new applications as BFCs for 68Ga.  It has been proved that the THP-peptide 
bioconjugates complex 68Ga quantitatively and rapidly at ambient temperature, 
neutral pH and micromolar concentrations of ligand. 68Ga-labeled THP-peptides 
accumulate at target tissue in vivo and are excreted largely via a renal pathway 
providing thus high quality PET-images. It has been concluded that THP-chelators 
can be used for simple, efficient labeling of 68Ga-biomolecules under mild 
conditions suitable for peptides and proteins (Ma et al. 2016, Cusnir et al. 2017). 
The acyclic hexadentate chelator 6,60-(ethane-1,2 diylbis(azanediyl)) 
bis(methylene)dipicolinic acid (H2dedpa) (Figure 3.) and its bifunctional 
derivatives are one example of acyclic chelators. Several H2dedpa derivatives, such 
as H2dedpa-propylpyr-FITC, H2dedpa-propylpyr-FITC-(N,N′-propyl-2-NI) and 
H2dedpa-propylpyr-NH2, have been prepared. All of these ligands possess strong 
68Ga coordinating atoms contained within dedpa2− that are ideal for radiolabeling 
with 68Ga3+ (Boros et al. 2010, Ramogida et al. 2016).  
In the series of 3-hydroxy-4-pyridinone (HPO)-based ligands, a hexadentate 
HPO chelator, CP256 and its bifunctional version YM103 (Figure 4.), have shown 
remarkable labeling efficiency at r.t. Radiochemical yield (RCY) of 98–100% after 
a 5-minute reaction time has been achieved. 68Ga-labeling succeeds also at low 
concentrations. The results indicate that the [68Ga]Ga-CP256 complex is highly 
stable for an acyclic chelator (Berry et al. 2011, Bartholomä 2012, Burke et al. 
2014). 
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Figure 3.  Examples of 68Ga-chelated acyclic chelators. 
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Figure 4.  HPO-based 68Ga-chelated ligands CP256 and YM103. 
2.2.1.3 Intermediate between macrocyclic and acyclic chelators 
6‐Amino‐1,4‐diazepinetriacetic acid (DATA) chelators (Figure 5.) are a class of 
tri‐anionic ligands. DATA chelators are intermediates between macrocyclic and 
acyclic chelators. They undergo quantitative radiolabeling more rapidly and under 
milder conditions as compared with macrocyclic chelators based on the cyclen 
scaffold like DOTA. Several DATA chelators (DATAm, DATAp, DATAPh and 
DATAPPh) have been labeled with 68Ga. Research has shown the extraordinary 
potential of this class of chelators for application in molecular imaging using 68Ga-
PET. It has been reported that the hexadentate DATAm ligand and its bifunctional 
analogue DATA5m rapidly form complexes with 68Ga in high RCY. At pH 7. 4 and 
at 25°C, the half-lives of the dissociation of [68Ga]Ga-DATAm and [68Ga]Ga-
DATA5m are 11 hours and 44 hours, respectively. Based on equilibrium and kinetic 
data, it has been suggested that the [68Ga]Ga-DATA5m complex is a good candidate 
as a 68Ga-based radiodiagnostic agent. (Seemann et al., 2015, Farkas et al., 2017, 
Nock et al., 2017)  
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Figure 5.  [68Ga]Ga-DATA chelator. 
2.2.2 Synthesis of 68Ga-labeled PET radiopharmaceuticals 
The RCY of a 68Ga-radiolabeling reaction is influenced by several different 
parameters, such as radiolysis, concentration, temperature, reaction time, pH value, 
stoichiometry, metal contamination of the precursor and the targeting agent itself. 
Typical radiolabeling conditions entail heating. The high temperature and low pH 
are unsuitable for many proteins of interest for molecular imaging. The long 
radiolabeling time allows extensive decay during labeling. In addition, the presence 
of metal ion impurities can affect the labeling efficiency. The labeling procedure 
has to be optimized for each targeting agent. Optimization is also needed to meet 
the requirements of radiolabeled products, which are high RCP and radiochemical 
stability. (Meyer et al., 2004, Petrik et al., 2011, Chakravarty et al., 2013, Seemann 
et al., 2015, Gijs et al., 2016, Tsionou et al., 2017) 
High molar activity of the final radiolabeled product is desired because high 
molar activity allows the administration of a minimal amount of unlabeled 
compounds. This might improve the signal-to-background ratios. Correspondingly, 
when administering lower doses of a PET radiopharmaceutical, simpler toxicology 
protocols and regulations can be applied. High molar activity can be obtained when 
the 68Ga-eluate from 68Ge/68Ga generator is highly concentrated and free of metal 
contaminants, when radiolabeling yields are quantitative and when the final 
product needs no further post-labeling purification. (Gijs et al., 2016) 
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2.2.2.1 Elution of the 68Ge/68Ga generator and pre-purification of the 
eluate 
The major limitations for the direct use of 68Ga in the radiolabeling of peptides for 
clinical PET applications are 68Ge breakthrough, potential metallic impurities, such 
as Zn2+ generated from the decay of 68Ga, titanium(IV) (Ti4+) or other potential 
impurities from the column material, as well as iron(III) (Fe3+), large volumes of 
generator eluate and high proton concentration (Zhernosekov et al., 2007, Ocak et 
al., 2010). The relatively high concentration of HCl may protonate functional 
groups of ligands and bifunctional ligands needed for the labeling of 68Ga. In 
principle, the long physical half-life of the parent 68Ge should allow the use of a 
generator for, at least, one year. (Rösch, 2013) 
Pre-purification of the eluate has several advantages especially for the 
radiolabeling of peptides. Pre-purification leads to the concentration of the eluate, 
which allows the use of all available activity for radiolabeling. It also ensures that 
accidental breakthrough of 68Ge is eliminated before radiolabeling and facilitates 
the removal of potential metallic impurities competing with the radiolabeling 
procedure. Metallic impurities may be present in the eluate, which may adversely 
affect the 68Ga yield as well as the molar activity of the labeled product. Several 
methods to purify the eluate from impurities have been developed. (Zhernosekov et 
al., 2007, Ocak et al., 2010, Boschi et al., 2013)  
One option is to use strong anion-exchange (SAX) resins (Hofmann et al., 
2001, Meyer et al., 2004, Velikyan et al., 2004) (Figure 6.). 68Ga is adsorbed on the 
micro-column, and the column is washed with 5.5 M HCl and flushed with a 
stream of nitrogen. The purpose of nitrogen is to blow off most of the strong HCl. 
68Ga is eluted from the micro-column by using pure water. This leads to the 
decomposition of the tetrachloro-complex and release of 68Ga as aqueous 68Ga3+. In 
order to concentrate 68Ga from generators eluted with 0.1 M HCl, the eluate is 
adjusted to a concentration of 5.5 M HCl by the addition of the required volume of 
30% HCl. As a result, 68GaCl4− is formed, and treated as described above. Both the 
pyrogallol/formaldehyde type and titanium dioxide-based generators have been 
tested successfully. It has been found that the concentration process will clean 68Ga 
from any potential 68Ge breakthrough. It does not provide sufficient purification of 
Ga3+ from, for example, Zn2+ and Fe3+. These could interfere with the 68Ga-labeling 
if present. (Meyer et al., 2004)  
It has been found that the best agent for eluting 68Ga from the small anionic 
cartridges is deionized water. Using the sodium acetate (NaOAc) solution directly 
as the eluting agent is not recommended because the recovery yield of 68Ga is very 
poor. This is most likely due to the anionic Ga-acetate complex adsorbing to the 
resin. 50% Ethanol (EtOH) has been proposed as an alternative eluting agent. It has 
shown nearly the same recovery properties as pure water alone. The parent nuclide 
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68Ge is not retained on the anion resin. This means that the concentration step can 
also be seen as a purification of 68Ga from 68Ge breakthrough. In the same way, the 
original generator eluate has been purified from Ti by 90%. With respect to the 
eluted 68Ga activity, the 68Ge breakthrough is 0.001–0.007%. (Velikyan et al., 
2004) 
 
Figure 6.  Schematic diagram of the 68Ge/68Ga generator eluate pre-purification methods. The 
68Ge/68Ga generator is eluted using 0.1 M HCl. The eluate can be purified using (1) 
strong anion-exchange (SAX) resin, (2) fractionation, (3) strong cation-exchange 
(SCX) resin with 97.6% acetone/0.05 M HCl, or (4) SCX resin with NaCl/HCl. (Modified 
from Mueller et al., 2012)  
Fractionation (Figure 6.) is one approach to overcome problems, such as content of 
68Ge and chemical impurities, acidic pH and eluate volume. The fractionated 
generator eluate has been used directly without any further purification step to 
achieve high molar activity of the radiolabeled peptide. Fractionation is based on 
the fact that about two-thirds of the total 68Ga activity elute within an activity peak 
of ~ 1–2 mL. Because of the low eluate volume used, the contents of 68Ge and 
metallic impurities are lower. However, they are not chemically removed before 
the 68Ga-labeling steps. This approach only decreases the metallic impurities but 
does not eliminate them. (Breeman et al., 2005, Zhernosekov et al., 2007, Asti et 
al., 2008, Boschi et al., 2013)  
An efficient and simplified method for the preparation of 68Ga-labeled PET 
radiopharmaceuticals using a microchromatography column containing cation-
exchange resins has also been reported (Figure 6.). Using this method, the eluted 
68Ga is purified from 68Ge, Zn2+, Ti4+ and even Fe3+. It has been proved that the 
significant removal of almost the entire 68Ge breakthrough on the SCX using the 
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97.6% acetone/0.05 M HCl systems fullfils the basic requirements relevant to the 
medical use of the radionuclide generator. The SCX resin represents a guarantee 
for avoiding the transfer of 68Ge breakthrough to the labeling system or to the 
patient. In addition, this method extends the useful life of the 68Ge/68Ga generator 
systems. It has been proposed that the initial 68Ge breakthrough of a newly installed 
generator may be acceptable but the breakthrough might increase as a consequence 
of frequent elutions. This limits the long-term or high-volume application of a 
generator. (Zhernosekov et al., 2007) 
It has been demonstrated that the amount of 68Ge4+ remaining in the free 
volume of the SCX column is further reduced by washing with the 80% 
acetone/HCl solutions. The final 68Ga-fraction contains <0.01% of 68Ge relative to 
the initial eluate. Zn2+ is quantitatively adsorbed (>99%) from the 0.1 M HCl eluate 
along with Ga3+. It has been found that Zn2+ is desorbed by the 80% acetone/HCl 
purification step, whereas Ga3+ remains on the resin. Ti4+ is almost completely 
adsorbed on the SCX resin directly from the 0.1 M HCl solution. The remaining 
Ti4+ is eluted from the SCX resin almost completely in 4 M HCl. This allows the 
column to be cleaned. For Fe3+, the best separation factors are provided at an HCl 
concentration of 0.1 M, but a large volume of the eluent has to be applied. An 80% 
acetone/0.15 M HCl solution provides the best ratio of eluted amounts of Fe 
relative to the loss of 68Ga. (Zhernosekov et al., 2007) 
A sodium chloride (NaCl)-based, highly efficient 68Ga-eluate concentration and 
labeling procedure for DOTA-conjugated peptides has been introduced. The 
method has been proposed to be well-suited for routine production and clinical use, 
and it has the potential to be expanded to other ligands as well. The procedure is 
based on the assumption that 68Ga adsorbed onto an SCX cartridge is elutable with 
a concentrated NaCl solution by conversion of adsorbed 68Ga3+ to 68GaCl4− anion in 
the presence of a high concentration of chloride anions (Figure 6.). The 68Ge/68Ga 
generator is eluted with 0.1 M HCl and generator eluate is collected and adsorbed 
onto the SCX cartridge and eluted using a mixture of 5 M NaCl/5.5 M HCl. It has 
been found that the 68Ga activity is almost quantitatively elutable directly from the 
SCX cartridge by addition of a minimal amount of HCl to the 5 M NaCl solution. It 
has been proved that also this eluate could be used directly for 68Ga-labeling of 
DOTA-conjugated peptides in buffered reaction mixtures. (Mueller et al., 2012) 
Pandey and co-workers used a cyclotron for producing 68Ga. After irradiation, 
the target dump was received in a collection vial along with a 1.6 mL water rinse of 
the target. The dump and rinse solutions were mixed and passed through a cation-
exchange column. The column was preconditioned by washing with 15 mL of 
water followed by air. Both 68Zn and 68Ga were effectively trapped on the cation-
exchange column. The column was washed with water after trapping to remove 
short-lived 11C and 13N isotopes. 68Zn was eluted from the column using 0.5 N 
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hydrogen bromide (HBr) in 80% acetone solution and collected in a separate vial, 
followed by a water rinse to remove any remaining HBr-acetone. 68Ga was finally 
eluted with 3 N HCl into a product vial. (Pandey et al., 2014) 
2.2.2.2 Buffer solutions and purification of 68Ga-labeled peptides 
Both pre-concentration methods and eluate fractionation use HCl in the eluent and 
thus require buffers for the correct pH adjustment necessary for the 68Ga 
complexation. Weak complexation capacity of the buffer is essential in order to 
prevent 68Ga3+ precipitation and colloid formation and thus act as a stabilizing 
agent. A number of buffering systems have been evaluated. (Ebenhan et al., 2017)  
As already mentioned, Ga3+ can form four-, five- and six-coordinated 
complexes. The coordination reaction of Ga3+ requires buffering. DOTA- and 
NOTA-derivatives can easily be labeled with 68Ga in a reproducible manner and 
with high yield in a buffer like acetate or 4-(2-hydroxyethyl) piperazine-1-
ethanesulfonic acid (HEPES) or in water. Buffers with weak complexing strength 
are used in labeling synthesis to keep 68Ga in solution, prevent precipitation and 
colloid formation and provide pH required for formation of the desired complex. 
Various buffers, such as NaOAc, HEPES, formate, glutamate, lactate, oxalate, 
succinate, tartrate and tris, have been investigated. Among these, NaOAc, HEPES 
and succinate have proven to be the most promising for labeling purposes. The use 
of HEPES buffer has resulted in preparation of tracers with higher molar activity as 
compared with NaOAc. Other buffers mentioned above have led to poor RCYs. 
(Velikyan et al., 2004, Bauwens et al., 2010, Velikyan, 2011, Boschi et al., 2013, 
Velikyan, 2013)  
HEPES is a biologically compatible buffer and provides high molar activity 
and high radioactivity incorporation (>95%) (Velikyan et al., 2004, Velikyan et al., 
2008, Bauwens et al., 2010, Velikyan et al., 2010). The drawback of using HEPES 
is that the European Pharmacopoeia (Ph. Eur.) defines this buffer as an impurity 
and sets it a specified limit (Ph. Eur., 2013, Pfaff et al., 2018). This means that, 
prior to clinical use, the PET radiopharmaceutical should be purified from HEPES 
and additional QC must be performed to ensure that the buffer does not exceed the 
limit. The use of NaOAc has the advantage of being approved for human use. 
(Bauwens et al., 2010, Velikyan, 2014, Gijs et al., 2016) 
Syntheses of [68Ga]Ga-DOTA peptides have originally been performed 
manually or by means of a semi-automated system (Figure 7.). In these procedures, 
open standard reagent vials containing peptide and pure preheated water are used. 
Buffers like NaOAc and HEPES buffer solution are applied (Velikyan et al., 2004). 
The pre-concentrated and purified 68Ga is added and the reaction mixture is heated. 
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Different options, such as heating in an oil bath (Meyer et al., 2004) or using 
microwave heating (Velikyan et al., 2004), are available (Boschi et al., 2013). 
Methods for the radiolabeling of peptides with 68Ga for clinical applications are 
required to provide PET radiopharmaceuticals within a short time period in high 
yields and with high molar activity and pharmaceutical quality. The possibility of 
quantitative incorporation of 68Ga into microgram amounts of DOTA-derivatized 
peptides is a major advantage of 68Ga over 18F. In general, DOTA-derivatives 
require a high temperature (80–100°C) for labeling with 68Ga. NOTA, and 
particularly conjugates of some of its bi-functional derivatives, mainly NODAGA, 
can be labeled at r.t. Under acidic conditions, the radiolabeling yield is >95% 
within 10 minutes. (Meyer et al., 2004, Velikyan et al., 2004, Zhernosekov et al., 
2007, Decristoforo et al., 2012, Boschi et al., 2013)  
After the heating step, the solution is transferred to a pre-conditioned C18 
reversed phase cartridge for purification by a solid phase extraction (SPE) (Figure 
7.). 68Ga-labeled peptides are retained on this type of column, while colloids, non-
incorporated 68Ga3+ and 68Ge4+ are not retained (de Blois et al., 2011). The cartridge 
is washed with water or NaCl and the 68Ga-labeled peptide is recovered from the 
cartridge with a very small volume of EtOH directly into the final product vial. The 
EtOH-eluate containing pure 68Ga-labeled peptide is dissolved in an appropriate 
volume of sterile NaCl or corresponding and sterilized by filtration through a 
membrane filter. A final EtOH-content even <5% is yielded. The manual and semi-
automated procedures facilitate the preparation of injectable 68Ga-labeled DOTA-
peptides within 20–30 minutes. (Meyer et al., 2004, Decristoforo et al., 2007, 
Gabriel et al., 2007, Zhernosekov et al., 2007)  
The influence of SPE on different parameters has been studied for labeling 
DOTA-TOC with 68Ga. It has been observed that, before and after SPE 
purification, RCP values increased, mainly due to the removal of colloidal 68Ga as 
determined by TLC. In addition, the content of 68Ge reduced by a factor of >100 
and pH values increased from 3.7 to 5.8. The fixation of the radiolabeled peptide 
on the SPE cartridge allows the removal of all other components used in the 
synthesis. It also allows washing with sterile NaCl or corresponding for injection 
after synthesis. It is suggested that SPE purification should be included even when 
pre-absorption of the eluate on an ion-exchange column is used as a part of the 
synthesis protocol. (Decristoforo et al., 2007) 
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Figure 7.  Schematic diagram of an automated system for 68Ga-labeling of peptides including 
generator elution. As an example, for the labeling of DOTA-conjugated peptides using 
the NaCl-based method, the 68Ge/68Ga generator is eluted with a total of 10 mL of 0.1 
M HCl. 68Ga of the generator eluate is collected on a SCX cartridge and eluted with 
minimal loss (1–2%) using a mixture of 5 M NaCl/5.5 M HCl. The eluate is slowly 
added to a reaction vial in a heating block containing buffer (1 M, 200–400 μL) and the 
DOTA-conjugated peptide (DOTA-Tyr3-octreotide (DOTA-TOC) or DOTA-Tyr3-
octreotate (DOTA-TATE), 40 μg) in 3 mL of water. The pH of the buffer solution is 
adjusted with glacial acetic acid to 4.5 beforehand. After mixing, the final pH of the 
radiolabeling reaction mixture is approximately 3.6. The reaction mixture is heated at 
90°C for 7 minutes and then neutralized with, for example, sterile saline or sodium 
phosphate buffer. 68Ga-labeled peptide is transferred to a solid phase extraction (SPE) 
cartridge for purification. The 68Ga-labeled peptide is eluted from the cartridge using 
EtOH, through a sterile filter into the final product vial and formulated using sterile 
NaCl. DOTA-TOC is radiolabeled using an automated synthesis module and the total 
duration of the synthesis is 14 minutes. (Mueller et al., 2012) (Modified from the 
Modular-Lab PharmTracer® schematic by Eckert & Ziegler Eurotope) 
2.2.3 Examples of 68Ga-labeled PET radiopharmaceuticals 
2.2.3.1 68Ga-somatostatin peptide derivatives 
Somatostatin is a cyclic peptide hormone that exerts different biological effects in 
various parts of the body, such as the gut, the pancreas, the brain, the pituitary and 
some components of the immune system. The effects include cell proliferation, 
inhibition of hormone secretion and modulation of neurotransmission. Five 
different somatostatin receptor subtypes (SSTR 1–5) have been cloned and 
characterized. They are responsible for different biological responses. Some of 
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these receptors are overexpressed in several human tumors, especially 
neuroendocrine tumors (NETs) and their metastases. SSTR 2 is the most 
representative subtype in NETs, SSTR 3 and SSTR 5 are also represented on NET 
cell surface. SSTRs have been found to be overexpressed also in breast cancer, 
prostate cancer, renal cell carcinoma, small cell lung cancer and malignant 
lymphoma. 68Ga-labeled DOTA-conjugated somatostatin derivatives for the 
diagnosis of NETs have been well established. Three derivatives are in use: 
DOTA-1-NaI3-octreotide (DOTA-NOC), DOTA-TOC and DOTA-TATE (Table 
1.). In terms of radiolabeling, e.g. yields and molar activity, there is no relevant 
difference between these somatostatin analogues. (Wild et al., 2003, Antunes et al., 
2007, Ambrosini et al., 2008, Decristoforo et al., 2012, Jalilian, 2016) 
It has been proved that [68Ga]Ga-DOTA-NOC detects significantly more 
lesions than the SSTR 2-specific radiotracer [68Ga]Ga-DOTA-TATE in patients 
with NETs (Jalilian, 2016). SSTR-PET with [68Ga]Ga-DOTA-TOC is superior for 
the detection of NETs as compared with diagnostic computed tomography (CT) 
and SPECT in various clinical situations like initial diagnosis, staging and follow-
up (Gabriel et al., 2007). Carcinoid tumors, which are rich in SSTR, show typically 
high-level uptake of [68Ga]Ga-DOTA-TOC (Jindal et al., 2010). The U.S. Food and 
Drug Administration (FDA) has approved [68Ga]Ga-DOTA-TATE as an imaging 
agent for the detection of NETs. (Hofmann et al., 2001, Jindal et al., 2010, Hofman 
et al., 2012, Ocak et al., 2013, Yang et al., 2014, Deppen et al., 2016, Barrio et al., 
2017, Mahajan and Cook, 2017) 
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Table 1.  Examples of 68Ga-labeled PET radiopharmaceuticals. 
68Ga-labeled PET radiopharmaceutical Mechanism Intended use  References 
[68Ga]Ga-DOTA-NOC 
 
Binds to 
SSTR 2, 
SSTR 3 and 
SSTR 5. 
Identification 
of tumor site 
and selection 
of patients as 
candidates 
for 
radioimmuno-
therapy. 
Ambrosini et 
al., 2009 
[68Ga]Ga-DOTA-TOC  
 
Binds to 
SSTR 2 and 
SSTR 3, 
lower affinity 
for SSTR 5. 
PET/CT 
imaging in the 
diagnosis of 
prostatic 
cancers, 
NETs, thyroid 
malignancies 
and 
meningiomas. 
Evaluation of 
primary lung 
cancers, 
particularly 
the small-cell 
form. 
Hofmann et 
al., 2001, 
Jindal et al., 
2010 
[68Ga]Ga-DOTA-TATE  
 
SSTR 2 
specific. 
Detection of 
NETs (high 
specificity 
and 
sensitivity), a 
major role in 
clinical 
practice of 
neuroendocri
ne and other 
somatostatin-
avid 
malignancies. 
Hofman et al., 
2012, 
Barrio et al., 
2017 
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68Ga-labeled PET radiopharmaceutical Mechanism Intended use  References 
[68Ga]Ga-PSMA-11 
 
PSMA is 
expressed in 
prostate 
cancer. 
PET imaging 
of prostate 
carcinomas. 
Silver et al., 
1997, 
Charron et 
al., 2016 
2.2.3.2 Prostate-specific membrane antigen 
Prostate-specific membrane antigen (PSMA), also called glutamate 
carboxypeptidase II, is a membrane-type zinc protease. PSMA appears to be highly 
expressed in normal prostate tissue as well as in primary and nodally metastatic 
prostate cancer. It has been shown that carcinomas arising in the kidney, colon and 
bladder do not appear to express PSMA. (Silver et al., 1997, Eder et al., 2014, Pfob 
et al., 2016) 
[68Ga]Ga-PSMA-HBED-CC, also known as [68Ga]Ga-PSMA-11 ((Glu-NH-
CO-NH-Lys-(Ahx)-[[68Ga]Ga-HBED-CC])) (Table 1.), is an extracellular PSMA-
ligand for PET imaging that has gained significant attention during the past years. 
Similarly 18F-labeled PSMA, such as 18F-PSMA-1007, have received increasing 
interest recently (Giesel et al., 2016, Cardinale et al., 2017, Giesel et al., 2017).  
The acyclic chelator HBED-CC linked to the PSMA ligand can selectively target 
the hydrophobic pocket of PSMA in prostate carcinomas. (Eder et al., 2014, 
Charron et al., 2016, Pfob et al., 2016, Baranski et al., 2018) 
It has been reported that HBED-CC forms three diastereomers during 68Ga-
complexation (Schuhmacher et al., 1992). In a standard labeling protocol, 
[68Ga]Ga-PSMA-HBED-CC is incubated at pH of ~ 4 and heated at 95°C. The 
thermodynamically favored diastereomer is formed. However, a small fraction of 
one of the other two formed diastereomers is still present in the reaction mixture 
and would be part of the final formulation prepared for patients. It is important to 
assess the biological activity of the two major diastereomers according to their 
biological activity in cell-based assays. (Eder et al., 2014)  
Other PSMA inhibitors that can be used as theranostic agents have been 
described as well. In comparison with PSMA-HBED-CC, DOTA-conjugated 
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PSMA inhibitor PSMA-617 seems to be more attractive for endoradiotherapy 
because of its lower spleen accumulation, higher tumor uptake at later time points, 
and the highly efficient clearance from the kidneys. It has been observed that 
[68Ga]Ga-PSMA-617 shows lesions of prostate cancer with high contrast, 
especially in late images. Maximal contrast of tumor lesions is usually seen 
between three and four hours after injection. (Afshar-Oromieh et al., 2015, 
Benešová et al., 2015) 
Table 2.  Examples of RGD-based 68Ga-labeled PET radiopharmaceuticals. 
68Ga-labeled PET radiopharmaceutical Mechanism Intended 
use  
References 
[68Ga]Ga-DOTA-RGD 
 
 
 
[68Ga]Ga-NOTA-RGD 
 
 
 
Binds to 
integrins αvβ3, 
αvβ5. 
Cancer 
theranostic, 
cardio-
vascular 
diseases. 
Chen et al., 
2016, 
Gnesin et 
al., 2017 
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68Ga-labeled PET radiopharmaceutical Mechanism Intended 
use  
References 
[68Ga]Ga-NODAGA-RGD  
 
[68Ga]Ga-DOTA-E-[c(RGDfK)]2 
 
Binds to 
integrin αvβ3. 
Integrin 
affinity and 
tumor 
uptake. 
Dijkgraaf et 
al., 2011 
2.2.3.3 RGD-based peptides 
Integrins play a very important role in tumor angiogenesis and metastasis (Chen, 
2011). Most of the integrin-targeting imaging tracers are based on the tripeptide 
Arg-Gly-Asp (RGD) acid sequence because of its high affinity and specificity for 
integrin αvβ3 (Chen et al., 2016). Several proteins of the extracellular matrix like 
fibrinogen, fibronectin and vitronectin interact with integrin ανβ3 via the RGD 
sequence. Molecular imaging of ανβ3 integrin expression with PET is a promising 
technique that allows for visualization of tumor angiogenesis. (Ruoslahti, 1996, 
Gilad et al., 2016, Lobeek et al., 2018) 
The feasibility of [68Ga]Ga-DOTA-RGD (Table 2.) binding to the αvβ3/αvβ5 
integrin in the assessment of the degree of inflammation and the vulnerability of 
atherosclerotic plaques has been studied (Haukkala et al., 2009). In addition to the 
monomeric DOTA-RGD peptide, a dimeric RGD-peptide ([68Ga]Ga-DOTA-E-
[c(RGDfK)]2 (Table 2.) (Dijkgraaf et al., 2011, Kiugel et al., 2014) and a tetrameric 
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RGD-peptide ([68Ga]Ga-DOTA-E{E[c(RGDfK)]2}2 (Dijkgraaf et al., 2011) have 
been evaluated for PET imaging in animal studies. (Haukkala et al., 2009, 
Dijkgraaf et al., 2011, Kiugel et al., 2014) 
Radiolabeling of NOTA-RGD (Table 2.) with 68Ga has been found to be 
straightforward and stable. [68Ga]Ga-NOTA-RGD was synthesized in high yield 
and found to be a promising radioligand for the imaging of angiogenesis with high 
affinity, high stability, high specificity and excellent pharmacokinetic properties. 
(Jeong et al., 2008) 
According to the results obtained, [68Ga]Ga-NODAGA-RGD (Table 2.) shows 
high affinity for integrin αvβ3, high metabolic stability, receptor-selective tumor 
uptake, good tumor to background ratios, low protein-bound activity and rapid, 
predominantly renal elimination. [68Ga]Ga-NODAGA-RGD can be produced 
straightforward with high RCP and high yield, thus making it suitable for synthesis 
in an automated system. NODAGA-RGD has been labeled with 68Ga in a fully 
automated, cGMP compliant process (Pohle et al., 2012). It has been demonstrated 
that [68Ga]Ga-NODAGA-RGD is well tolerated and metabolically stable in 
humans. (Haubner et al., 2016)  
2.2.3.4 Oligonucleotides 
Oligonucleotides are short, single- or double-stranded deoxyribonucleic acid 
(DNA) or ribonucleic acid (RNA) molecules 
(Figure 8.). They include ASO, RNA interference 
(RNAi) and aptamer RNAs. Both ASO- and RNAi-
oligonucleotides are mainly intended for 
modulating gene and protein expression. Aptamers 
are single-stranded DNA or RNA sequences that 
can bind to proteins with high affinity. Aptamers 
have features that make them ideal candidates for 
use in therapeutics, diagnostics and other 
applications. (Syed and Pervaiz, 2010, Kerlin and 
Li, 2013, Gijs et al., 2016) 
Oligonucleotides are soluble in water. They are particularly chemically stable 
molecules. This is because of the robustness of their phosphodiester backbone. 
Oligonucleotides can be advantageous in comparison with proteins and antibodies 
because of their low toxicity, immunogenicity and smaller size. Oligonucleotides 
are chemically synthesized with high batch fidelity. In addition, they can be easily 
chemically modified to enhance their bioavailability, pharmacokinetics and 
stability. However, any modifications of oligonucleotides must be made without 
compromising their specificity or hybridization properties. Oligonucleotides are 
Figure 8. Schematic illustration          
of an oligonucleotide. 
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quite unreactive molecules and radiolabeling usually requires functionalization of 
oligonucleotides with a reactive group. This reactive group can be introduced 
during chemical synthesis without difficulty by the use of functionalized 
nucleotides. Nucleotides are easily functionalized with reactive groups, such as an 
alkyne, alkyl amino group, disulfide group or other, which can be introduced at the 
5′- or 3′-end or internally. (Roivainen et al., 2004, Winkler, 2013, Gijs et al., 2016) 
Turning oligonucleotides into PET radiopharmaceuticals is not straightforward 
and there are several challenges. Harsh chemical conditions can affect the stability 
of oligonucleotides. Oligonucleotides are sensitive to slow acid-catalyzed 
depurination. They can be hydrolyzed completely at high temperatures and very 
low pH. Oligonucleotides precipitate in most organic solvents. At least part of 
these properties are attributed to oligonucleotides’ hydrophilicity, ready interaction 
with degrading enzymes and multiple anionic charges. (Winkler, 2013, Gijs et al., 
2016) 
Various radiolabeling conditions like temperature, buffer system, incubation 
time and oligonucleotide concentration have been optimized in order to obtain 
68Ga-labeled oligonucleotides with high stability and high labeling efficiency. It 
has been suggested that radiolabeling of oligonucleotides should occur in pH 
conditions close to neutral to avoid hydrolysis or acid-catalyzed depurination 
during the labeling process. (Gijs et al., 2016) 
Esterified precursors of DOTA and NOTA ligands bearing a 
dimethoxytritylated hydroxyl side arm have been prepared and immobilized via an 
ester linkage to long chain alkylamine derivatized controlled pore glass. After that, 
oligonucleotide chains are assembled on the hydroxyl function, and the conjugates 
are released and deprotected. The 3′-DOTA- and 3′-NOTA-conjugated 
oligonucleotides thus prepared are converted to 68Ga-chelators (Figure 9.)  
Labeling of the conjugates has proven to be straightforward. According to the 
results obtained by in vivo imaging with PET, differences in biodistribution were 
mainly caused by oligonucleotide length and/or sequence, and marginally by the 
chelators. (Kiviniemi et al., 2012) 
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Figure 9.  68Ga-labeling of 3′-NOTA-conjugated oligonucleotide. 68Ga is obtained from a 
68Ge/68Ga generator by elution with HCl. NaOAc is added and the pH is adjusted to 3.5 
with HCl. NOTA-conjugate is added and the reaction mixture is incubated at 95°C for 
10−15 minutes. (Modified from Kiviniemi et al., 2012) 
Three different forms of oligonucleotides, namely 2′-deoxyphosphodiester, 2′-
deoxyphosphorothioate and 2′-O-methyl phosphodiester, have been researched. 
These oligonucleotides are conjugated to the DOTA-chelator before radiolabeling 
with 68Ga. NaOAc buffer is added to the eluate obtained from the 68Ge/68Ga 
generator to give pH 5.5. DOTA-oligonucleotide is added and the mixture is 
incubated at 100°C for 10 minutes. The [68Ga]Ga-DOTA-oligonucleotide remains 
stable in water at r.t. for up to four hours. According to researchers’ experience, the 
method is easily transferable between laboratories and requires only minor 
investments. (Roivainen et al., 2004) 
68Ga-labeling of DOTA-oligonucleotides using microwave activation has also 
been described. Microwave activation is used to speed up the complexation of 68Ga 
with the DOTA chelator. Four modified and functionalized 17-mer 
oligonucleotides with a hexylamine group in the 3′- or 5′-position have been 
researched. These oligonucleotides are conjugated to the DOTA chelator and 
radiolabeled with 68Ga successfully. The same reaction mixture as described above 
is vortexed and microwave activation is applied for one minute. It has been found 
that the modifications of the oligonucleotides, such as the substitution of non-
bridging oxygens by sulfur, introduction of hexylaminolinker either at the 3′- or 5′-
end or introduction of O-methyl group at sugar 2′-position, do not influence the 
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radiolabeling and conjugation result or the hybridization ability of the 
oligonucleotides. Radiolabeled products are stable in water and EtOH over four 
hours. (Velikyan et al., 2004) 
 
Figure 10. 68Ga-labeling of 2′-O-methyl oligoribonucleotide bearing one D-galactopyranoside 
residue. 68Ga is obtained from a 68Ge/68Ga generator by elution with HCl. NaOAc 
buffer is added and the pH is adjusted to 3.5 with HCl. An oligonucleotide conjugate is 
added and the reaction mixture is incubated at 95°C for 10−15 minutes. (Modified from 
Mäkilä et al., 2014) 
Biokinetics of 68Ga-labeled oligonucleotides in rats has been examined. 
Intravenously (i.v.) injected 68Ga-oligonucleotides of 17-mer length have resulted 
in high-quality PET images and thus allowed for quantification of the biokinetics in 
tumors and major organs. The results show that the simple and rapid 68Ga-labeling 
of oligonucleotides is a convenient approach for in vivo PET imaging of the 
biodistribution and quantification of oligonucleotide biokinetics in living animals. 
(Roivainen et al., 2004) 
2.2.3.5 MicroRNA 
MicroRNAs (miRNAs) are a class of short non-coding RNAs that have been 
demonstrated to regulate the expression of genes governing tumorigenic processes 
by targeting mRNAs for translational inhibition or degradation (Xia et al., 2017). 
Changes in miRNA expression profile are correlated with cancer progression, 
tumor pathogenesis and drug resistance (Calin and Croce, 2006). For example, it 
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has been shown that microRNA-21 (miR-21) is overexpressed in all kinds of 
tumors. miR-21 has been demonstrated to play an important role in the 
radioresistance of cancers, including breast cancer, glioblastoma and rectal cancer 
(Xia et al., 2017). It has been demonstrated that miR-21 is significantly 
overexpressed in osteosarcoma tissues. The results suggest that miR-21 expression 
plays a key role in regulating cellular processes in osteosarcoma, and it may serve 
as a therapeutic target. (Ziyan et al., 2011) 
68Ga-radiolabeled 2′-O-methyl oligoribonucleotides (anti-miR-15b) bearing one 
(Figure 10.), three or seven D-galactopyranoside residues have been prepared. In 
vivo imaging with PET in rats has shown remarkable galactose-dependent liver 
targeting for the conjugates. (Mäkilä et al., 2014) 
2.2.3.6 Bis(phosphonates) 
Bis(phosphonates), which are pyrophosphate (PP) analogs, are the most widely 
utilized bone-binding ligands. This is due to the fact that the molecular structure of 
bis(phosphonates) greatly affects the binding affinity to hydroxyapatite mineral. 
This binding affinity has led to the widespread use of bis(phosphonates) as drugs to 
treat metabolic bone disorders. Bis(phosphonates) have been synthesized as a more 
chemically stable analog of PP. The oxygen molecule bound to the two 
phosphonate molecules in pyrophosphate (P-O-P) is replaced by a carbon (P-C-P). 
This elemental substitution results in bonds that are resistant to degradation. 
Substitution also creates biologically active molecules that are similar in structure 
to PP and capable of being delivered to bone in vivo without degradation by 
hydrolysis. The first synthesized and studied bis(phosphonates) have shown to 
significantly impair in vivo bone resorption in rats. This has increased interest in 
exploring bis(phosphonate) compounds as therapeutic agents for bone diseases. 
(Francis et al., 1969, Cole et al., 2016) 
The idea of conjugating bis(phosphonates) to proteins that promote bone 
formation and healing was introduced almost twenty years ago. A 
bis(phosphonate), 1-amino-1,1-diphosphonate methane, was conjugated to a 
protein, albumin. According to the results, the conjugated albumin exhibited a high 
affinity to hydroxyapatite, which was proportional to the extent of conjugation. It 
was concluded that conjugation of bis(phosphonates) to albumin imparted a high 
bone affinity to the protein. These conjugates can be potentially targeted to bone. 
However, it has been shown that most proteins do not exhibit specific binding to 
hydroxyapatite but have ubiquitous targets throughout the body. This means that 
bis(phosphonate) molecules could be conjugated to proteins to reduce the required 
dose, improve bone-targeting and reduce extraosseous accumulation of the 
proteins. Studies where bis(phosphonates) have been conjugated to many model 
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proteins, such as bovine serum albumin, IgG and lysozyme, have been performed. 
These studies suggest that bis(phosphonates) can be used as a targeting ligand to 
deliver proteins to bone tissue. (Uludag et al., 2000, Cole et al., 2016) 
A promising DOTA-conjugated bis(phosphonate), 4-{[(bis-phosphonomethyl)-
carbamoyl]methyl}-7,10-bis(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl-
acetic acid (BPAMD, also called DOTAMBP) (Figure 11.), has been radiolabeled 
with 68Ga. Optimum reaction parameters for the 68Ga-complex formation were 
identified through variation of reaction pH (pH = 1−5), reaction time (1−10 
minutes), temperature (60°C to 100°C) and different amounts of the complex 
ligands. The results of radiolabeling kinetics showed best efficiency at pH = 3−5 
and at 100°C for 10 minutes. Complex formation of [68Ga]Ga-BPAMD is reported 
to be fast and resulting in high yields. (Fellner et al., 2012, Meckel et al., 2013) 
In addition, two DOTA-based bis(phosphonates), 4-{[(bis-phosphonopropyl)-
carbomoyl]methyl}-7,10-bis-(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl-
acetic acid (BPAPD, also called DOTAPBP) and tetraethyl-10-{[(2,2-bis-
phosphonoethyl)hydroxyl-phosphoryl]methyl}-1,4,7,10-tetraazacyclododecane-
1,4,7-triacetic acid (BPPED, also called DO3APBP), have been radiolabeled with 
68Ga (Figure 11.). According to the results high bone uptake values were observed 
for all these three 68Ga-labeled bis(phosphonates) at 60 minutes post injection. The 
results obtained suggest that these ligands could be useful in 68Ga imaging of bone 
metastases. (Meckel et al., 2013) 
68Ga-radiolabeling of NOTA-like ligands with a bis(phosphonate)-containing 
side arm connected to a metal-binding cage through acetamide (1,4,7-
triazacyclononate-1,4,7-triacetamide, NOTAMBP) or methylphosphinate (1,4,7-
triazacyclononane-1,4-diacetic acid, NO2APBP) pendant arms has also been 
described. According to the results, they showed efficient complexation of 68Ga. It 
was reported that the phosphinate derivative was shown to bind metal ion better 
than the acetamide derivative under any used conditions. Radiolabeling with 68Ga 
was rapid at temperatures above 60°C for the phosphinate and at 90°C for the 
acetamide ligand. (Holub et al., 2015) 
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Figure 11. 68Ga-labeling of BPAPD and BPPED. Radiolabeling is performed in ammonium 
acetate buffer by adding the processed 68Ga-eluate, thus giving a labeling pH of 3.75. 
The ligand is added and the solution is shaken in a heating block for 10 minutes at 
100°C. (Modified from Meckel et al., 2013) 
2.2.3.7 Sialic acid-binding immunoglobulin-like lectin 9 
Sialic acids are α-keto acids and they consist of a 9-carbon backbone. Sialic acids 
are located at the distal part of the non-reducing end of glycan and thus they play a 
special role in physiological processes. Siglecs are single-pass transmembrane cell-
surface proteins found predominantly on leukocytes. Siglecs are characterized by 
their ability to bind specific sialic acid structures. The Siglec family is divided into 
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two subsets, a rapidly evolving CD33-related subset and a highly conserved subset. 
Both groups include both activating and inhibitory receptors. Siglecs are mostly 
located on the cell surface of hematopoietic cells (Varki and Angata, 2006), but 
cells outside the immune system can also express Siglecs. (Bornhöfft et al., 2018, 
Carroll et al., 2018) 
Human primary amine oxidase, also known as VAP-1, is an endothelial cell 
molecule involved in leukocyte trafficking from blood into the tissues during 
inflammatory responses. VAP-1 is stored in vesicles in the endothelial cells and, 
upon inflammatory stimuli, it is expressed on the endothelial cell surface and 
prevails there during inflammation (Salmi and Jalkanen, 2014). This makes VAP-1 
a good target for visualizing inflammation. Siglec-9 peptides targeted to VAP-1 
have been used for PET imaging of inflammation and cancer using different animal 
models. (Li et al., 2013, Virtanen et al., 2015, Retamal et al., 2016, de Carvalho et 
al., 2018) 
The cyclic peptide CARLSLSWRGLTLCPSK, containing residues 283−297 
from Siglec-9 and with cysteines forming a disulfide bridge, has been identified as 
a VAP-1 ligand (Aalto et al., 2011). The 68Ga-labeled tracer [68Ga]Ga-DOTA-
Siglec-9 contains an 8-amino-3,6-diooxaoctanoyl linker, which is a polyethylene 
glycol derivative, between the peptide and DOTA chelator. Radiolabeling of 
DOTA-Siglec-9 and another VAP-1-selective peptide named DOTAVAP-P1 has 
been described (Figure 12.). (Ujula et al., 2009, Aalto et al., 2011, Virtanen et al., 
2015) 
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Figure 12.  68Ga-labeling of DOTA-Siglec-9 (top) and DOTAVAP-P1 (bottom). 68Ga is obtained 
from a 68Ge/68Ga generator by elution with 0.1 M HCl. 68Ga-eluate is mixed with 
HEPES to give a pH of approximately 4.1 (DOTA-Siglec-9) or with NaOAc to give a pH 
of approximately 5.5 (DOTAVAP-P1). Peptide is added and the reaction mixture is 
heated at 100°C for 15 minutes (DOTA-Siglec-9) or at 100°C for 20 minutes 
(DOTAVAP-P1). No further purification is performed. (Modified from Ujula et al., 2009, 
Virtanen et al., 2015) 
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2.2.4 Quality control of PET radiopharmaceuticals 
PET radiopharmaceuticals are treated as drugs. It is required that the effect, i.e. the 
PET image quality, is guaranteed throughout the PET radiopharmaceutical’s shelf 
life. QC of PET radiopharmaceuticals is important to ensure the safety of the 
product before its release for clinical use. Because these compounds are injected 
into humans, there are strict regulatory requirements for performing QC testing of 
the purified, formulated product of each produced batch to ensure their safety 
(Fermi, 2009). PET radiopharmaceuticals have to be manufactured, QC tested and 
administered to patients within a short period of time due to the short half-life of 
the radionuclides. Because the half-life ranges from minutes to hours, there is no 
time for all quality parameters to be assessed before releasing the PET 
radiopharmaceutical for clinical use. In compliance with the risk assessment, it 
must be specified which parameters can be determined retrospectively. Such 
parameters include the determination of levels of residual solvents and sterility 
testing. Sterility testing is performed post release. As a surrogate of sterility testing, 
endotoxin testing should be performed before release, if possible. (Ballinger and 
Koziorowski, 2017, Ha et al., 2017, Lodi and Boschi, 2017, Schmidt et al., 2017) 
Several quick and efficient tests have been adopted to check the quality of PET 
radiopharmaceutical preparations before they are released for clinical use in 
nuclear medicine. Specific procedures for QC of PET radiopharmaceuticals have 
been published in each country or region (Ph. Eur., United States Pharmacopeia 
and British Pharmacopoeia). QC of PET radiopharmaceuticals involves several 
specific tests and measurements to ensure product purity, identity, efficacy and 
biological safety. The QC tests can be divided into chemical tests, physical tests 
and biological tests. The chemical and physical tests include, among other things, 
the visual inspection, the control of pH, and the chemical purity, RCP and 
radionuclidic purity determination. Biological tests establish sterility and bacterial 
endotoxins contents. Performing and documenting these required QC tests is time-
consuming and cumbersome. It requires, at least, an array of expensive analytical 
chemistry equipment and significant dedicated laboratory space. For most tests, 
visual assessment and manual handling and loading of samples leads to significant 
radiation exposure to personnel. (Ha et al., 2017, Lodi and Boschi, 2017) 
Another way to categorize tests is to divide them into radioactive tests and 
pharmaceutical tests. Radioactive test, such as RCP, radiochemical identity, 
radioactivity concentration (RAC), radioisotope identity and radioisotope purity, 
are required to ensure that there are no radionuclidic or radioactive impurities that 
could interfere with the biodistribution or imaging protocol. Pharmaceutical tests 
involving, for example, color and clarity, pH, chemical purity, residual solvents, 
pyrogenicity and sterility, are required to ensure the physiological compatibility of 
the final preparation and the absence of microbiological, pyrogenic, chemical or 
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particulate contamination. The goal is to ensure the proper patient dose. (Ha et al., 
2017, Lodi and Boschi, 2017) 
2.2.4.1 Chemical and physical tests 
Visual inspection of the PET radiopharmaceutical solution should be performed 
before clinical use to ensure that the injectable solution is free from particle 
contaminations. The purpose is to confirm the color, turbidity or absence of visible 
particles. The color and clarity of each PET radiopharmaceutical preparation 
should be checked and the appearance characteristics are reported in the 
monograph on the radiopharmaceutical. In general, only a clear and colorless, 
particle-free solution should be used for injection. Generally, the test is performed 
manually via a qualitative visual inspection. This results in variability in the 
readout. Formulated PET tracers are generally colorless due to the lack of 
appreciable absorbance by the tiny amounts of tracer used. Any coloration would 
indicate a significant quantity of an impurity. (Ha et al., 2017, Lodi and Boschi, 
2017, Schmidt et al., 2017) 
pH must be controlled to ensure the stability of the formulated PET 
radiopharmaceutical and to establish that no degradation has occurred between 
manufacturing and injection. In addition, the physiological compatibility of the 
formulated PET radiopharmaceutical with the patient should be controlled. The pH 
of a preparation can be checked using a pH paper indicator strip or a calibrated pH 
meter. PET radiopharmaceuticals must be formulated at appropriate pH. Due to the 
relatively small injection volume, typically 1–10 mL, and the high buffer capacity 
of the blood, a relatively wide pH range, typically 4.5–8.5, is considered to be 
acceptable from a physiological point of view. (Ha et al., 2017, Lodi and Boschi, 
2017, Schmidt et al., 2017) 
The radionuclidic identity of PET radionuclides is generally identified by half-
life or by gamma-ray spectrometry or by both. The half-life is determined within a 
suitable period of time, for example 15 minutes, by taking a minimum of three 
radioactivity measurements of a sample. All these measurements have the same 
geometry. The half-life is measured with a suitable detection apparatus, such as a 
Geiger-Müller counter, a scintillation counter or an ionization chamber. (Ph. Eur., 
2013, Lodi and Boschi, 2017) 
RAC has to be measured in every batch of the final drug preparation at the end 
of synthesis (EOS) (Fermi, 2009). The total amount of radioactivity in the vial 
containing the final drug preparation is usually measured using a calibrated dose 
calibrator. RAC is needed to determine how much volume to dispense for each 
individual patient dose, meaning decay-corrected to the expected time of injection. 
(Ha et al., 2017, Schmidt et al., 2017) 
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Enantiomeric purity has to be verified where appropriate. In the clinical use of 
chiral PET radiopharmaceuticals, high enantiomeric purity is important. The limit 
for each enantiomeric impurity is reported in the pharmacopoeia monograph of the 
radiopharmaceutical, if it has such. (Lodi and Boschi, 2017) 
Radiochemical identity can be defined as the molecular structure of the 
compound that contains the positron-emitting radionuclide. The radiochemical 
identity of a PET radiopharmaceutical is determined by using a non-radioactive 
reference standard. Both the standard and the PET radiopharmaceutical are 
analysed chromatographically. An identical response for the two compounds in 
terms of retention time when using HPLC with a radiation detector (radio-HPLC), 
retardation factor when using radio TLC scanner (radio-TLC) or migration time 
when using capillary electrophoresis (CE) with a radiation detector (radio-CE), 
demonstrates the structural identity of the PET radiopharmaceutical. (Ha et al., 
2017, Lodi and Boschi, 2017) 
In addition to confirming the identity of the product, it is also necessary to 
ensure the absence of radioactive impurities. RCP is defined as the ratio of the 
activity of the radionuclide concerned which is present in the PET 
radiopharmaceutical preparation in stated chemical form, to the total radioactivity 
of that radionuclide present in the PET radiopharmaceutical preparation. RCP is 
expressed as a percentage. The nature of contaminants will depend on the 
radionuclide production, on the production process of the PET radiopharmaceutical 
and the impurity profile of the used starting material. (Ha et al., 2017, Lodi and 
Boschi, 2017) 
The control of radiochemical impurities is essential because any radiochemical 
impurity can potentially affect the biodistribution of the PET radiopharmaceutical, 
thus giving a misleading imaging result. It is also important to avoid the patient 
being subjected to unnecessary radiation exposure. Measurement of RCP requires 
the use of a method to separate the different labeled chemical species which may 
be present in the PET radiopharmaceutical preparation. (Ha et al., 2017, Lodi and 
Boschi, 2017) 
Chromatographic methods are commonly used in radiochemical determination 
because they can effectively separate and quantify the radioactive species in the 
sample. RCP is typically determined via radio-HPLC. In addition, for accurate 
determination of RCP, an analysis by radio-TLC may also be necessary. This is 
because of the fact that certain radioactive species can be under-represented in 
HPLC. For 68Ga-labeled radiopharmaceuticals, RCP by HPLC is the main test that 
must be performed before medical use to determine the percentage of free 68Ga. 
The presence of 68Ga in colloidal form is possible to check, for example, by TLC. 
In general, the RCP should be >95%. (Lamesa et al., 2015, Ha et al., 2017, Lodi 
and Boschi, 2017, Schmidt et al., 2017)  
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Radionuclidic purity is the ratio of the desired radionuclide activity to the total 
activity. Radionuclidic purity is expressed as a percentage. The purpose of testing 
radionuclidic purity is to ensure that the PET radiopharmaceutical is not 
contaminated with other radionuclides. While using 68Ge/68Ga generators, the 
potential breakthrough of 68Ge with eluted 68Ga must be taken into account. 
Cyclotron production of 68Ga eliminates the possibility of 68Ge breakthrough. 
Radionuclidic impurities can impact the image quality and contribute significantly 
to the patient’s overall radiation dose. The pharmacopoeia monographs prescribe 
the required radionuclidic purity and may set limits for specific radionuclidic 
impurities. (Ha et al., 2017, Lodi and Boschi, 2017, Schmidt et al., 2017, Lin et al., 
2018) 
Chemical purity concerns non-radioactive materials in PET 
radiopharmaceuticals. It involves by-products, solvents and other residual 
components used in the production process as well as non-radioactive materials 
like additives and stabilizers that are intentionally added to the PET 
radiopharmaceuticals. All non-radioactive substances that can either affect 
radiolabeling or directly produce adverse biological effects in patients are 
considered chemical impurities. (Ha et al., 2017, Lodi and Boschi, 2017)  
In pharmacopoeia monographs chemical purity is controlled by setting specific 
limits on chemical impurities. Impurities are typically determined by 
chromatographic techniques. For example, HPLC or TLC can be used to 
characterize and determine the quantity of potential chemical contaminants in the 
final product. The purpose of testing is to ensure that the purification process has 
reduced residual amounts of impurities to below allowed limits. Impurities are 
typically quantified using HPLC combined with ultraviolet (UV) absorbance 
detection (HPLC/UV). Ultra performance liquid chromatography (UPLC) is also 
used for analysing PET radiopharmaceuticals (Franck et al., 2009, Kryza and 
Janier, 2013). This technique offers the advantages of faster separation times and 
more compact separation columns. For those PET radiopharmaceuticals that are 
labeled by a chelation reaction, the most significant impurity is unlabeled 
radioisotope, which can be detected via radio-TLC. (Ha et al., 2017, Lodi and 
Boschi, 2017)  
The identity of each peak in the detected chromatogram is determined by 
comparison of retention time with reference standards. The quantity is generally 
determined from the peak area. In the case of known impurities, the amount present 
in the sample is compared with allowed regulatory limits. Regarding unknown 
impurities, as long as these impurities are below the limit of observed adverse 
effects in preclinical toxicology studies, they may be safe for injection. (Ha et al., 
2017) 
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Residual solvents are defined as organic volatile chemicals that are used or 
produced in the manufacture of drug substances or excipients, or in the preparation 
of drug products. Residual solvents may be the result of the PET 
radiopharmaceutical synthesis or originate from packaging and storage. Residual 
solvents in the final formulation may exhibit a variety of toxic effects. The 
remaining amounts of all solvents used during the synthesis and purification 
process must be monitored to ensure residual amounts are below safe limits. For 
example, Ph. Eur. sets a specified limit for EtOH content (Ph. Eur., 2013). Residual 
solvents are usually determined by chromatographic techniques such as gas 
chromatography (GC) in conjunction with a flame ionization detector (FID). (Ha et 
al., 2017, Lodi and Boschi, 2017) 
2.2.4.2 Biological tests 
One example of a QC criterion specific to short-lived PET radiopharmaceuticals is 
the permission to release them before completion of all tests. PET 
radiopharmaceutical preparations must be manufactured using precautions 
designed to exclude microbial contamination and to ensure sterility. However, 
sterility tests, for example, are not compatible with the short half-life. Thus, 
sterilization of the final product or final sterile filtration (0.22 µm filter) and 
performance of a filter integrity test, bubble point test, is required prior to the 
release. (Ha et al., 2017, Lodi and Boschi, 2017, Schmidt et al., 2017) 
The test for sterility is carried out under aseptic conditions by inoculating the 
sample in two culture media, and by incubating for not less than 14 days. Because 
the timeframe is much longer than the half-life of PET radioisotopes, a quick, 
short-term test is allowed to be used to facilitate early release of the PET 
radiopharmaceutical. In the short-term test, the integrity of the filter membrane is 
assessed, typically via a bubble point test, after completing sterile filtration. 
Compressed gas is applied to the inlet of the wetted filter and pressure is increased 
until bubbling appears at the outlet, the bubble point. If the bubble point exceeds a 
threshold pressure, it can be assured that the membrane is intact and pores do not 
exceed the specified size. A drawback of this test is that the operator has to 
manually handle the active filter membrane. (Ha et al., 2017, Lodi and Boschi, 
2017) 
Bacterial endotoxins (pyrogens) are polysaccharides from bacterial gram-
negative membranes which are heat stable, water-soluble and filterable. Their 
presence in a PET radiopharmaceutical preparation can cause fever and also 
leucopenia in immunosuppressed patients. To minimize the presence of pyrogens, 
it is important that preparations are manufactured and dispensed under aseptic 
conditions. Endotoxins can contaminate a solution even if the bacteria have been 
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thoroughly removed via sterile filtration. Therefore, it is necessary to test PET 
radiopharmaceutical formulations for the presence of endotoxins. Modern 
automated endotoxin testers are able to provide valid results within a few minutes. 
Bioburden analysis can be achieved by running synthetic steps without 
radioactivity. The effluent is collected at intermediate steps and at the endpoint of 
the synthetic process without filter sterilization and subsequent sterility testing. 
(Elsinga et al., 2010, Ha et al., 2017, Lodi and Boschi, 2017, Schmidt et al., 2017) 
2.2.4.3 Examples of analytical techniques used in quality control of PET 
radiopharmaceuticals 
Chromatographic separation methods are commonly employed in the QC of PET 
radiopharmaceuticals. Chromatography is an analytical technique based on the 
separation of two or more compounds by the distribution between two phases, a 
stationary phase and a mobile phase. The two phases can be solid-liquid, liquid-
liquid or gas-liquid. Chromatographic separation methods are commonly employed 
in radiochemical, chemical and enantiomeric purity determinations. HPLC, TLC 
and GC are commonly used chromatographic methods. (Lodi and Boschi, 2017) 
 
Figure 13.  HPLC system. (Waters Corporation, 2014) 
HPLC is a type of liquid chromatography used to separate and quantify compounds 
that have been dissolved in a solution. HPLC consists of a number of components, 
including reusable columns that hold packing material, stationary phase, and high 
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pressure pumps that move the mobile phase through the columns (Figure 13.). 
Column packings consist of small particles designed to provide high separation 
efficiencies. Other components are an injector to introduce the sample in a small 
volume and a detector that shows the retention time of the molecules for 
identification and quantitation. Retention time varies depending on the specific 
chemical or physical interactions between the stationary phase, the solvent used as 
a mobile phase and the molecules being analysed. The coupling of radioactivity 
detectors to the system makes it possible to apply HPLC to PET 
radiopharmaceuticals. Radioactivity detectors are used to determine the RCP. The 
ratios of the areas under the peaks give the ratios or percentage of the RAC of the 
compounds. In addition, the retention time of each compound allows for 
radiochemical identification. This is performed by comparing the solutions of the 
same non-radioactive chemical substances, referred to as “cold standard”, using a 
suitable detection method. (Nunn and Fritzberg, 1986, Lodi and Boschi, 2017)  
Types of HPLC generally depend on the phase system used in the process. 
Normal-phase chromatography (NP-HPLC), reversed-phase chromatography (RP-
HPLC) and ion-exchange chromatography are the commonly used types of HPLC 
in the QC of PET radiopharmaceuticals. NP-HPLC separates analytes based on 
polarity. RP-HPLC has a non-polar stationary phase and an aqueous, moderately 
polar mobile phase. RP-HPLC operates on the principle of hydrophobic 
interactions. They result 
from repulsive forces 
between non-polar stationary 
phase, the relatively non-
polar analyte and a polar 
eluent. Polar compounds are 
weakly retained and are 
rapidly eluted by largely 
aqueous solvent systems. 
Non-polar compounds are 
more strongly retained and 
require increased proportions 
of organic solvent for 
elution. The most common 
type of packing for RP-
HPLC is silica gel to which 
non-polar or alkyl groups are 
covalently attached. (Nunn 
and Fritzberg, 1986, Lodi 
and Boschi, 2017)  
Figure 14. Principle of TLC and development of the plate. 
(Modified from Lodi and Boschi, 2017) 
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TLC is based on distribution of analyte between a thin layer of sorbent on a 
solid support and liquid phase moving along the sorbent by capillary force. TLC 
technique can be used to verify RCP. A small sample of the PET 
radiopharmaceutical is applied on the marked origin spot on the TLC plate (Figure 
14.) and the TLC plate is placed in the development chamber filled with a small 
amount of mobile phase. The solvent travels from the bottom of the chamber up to 
the layer of adsorbent by capillary action, passes over the spot and moves the 
compounds in the mixture up the plate at different rates. The result is the separation 
of the compounds due to the differences in their affinity to the stationary phase and 
because of differences in solubility in the solvent. The position of radioactive spots 
is detected by autoradiography or by measurement of radioactivity over the length 
of the chromatogram using suitable collimated counters (Figure 14.). TLC can also 
provide a chromatographic measurement known as retardation factor. (Lodi and 
Boschi, 2017)   
GC is a gas-liquid chromatography which involves a sample being vaporized 
and injected onto the head of the chromatographic column (Figure 15.). GC is a 
technique for the separation of components of mixtures. GC consists of the 
capillary, i.e. the open-tubular column, liquid and solid stationary phases, carrier 
gas as the mobile phase, the key mechanisms of the interaction of the solutes 
migrating through a column with the stationary phase, as well as temperature and 
pressure programming. The sample is transported through the column by the flow 
of inert, gaseous mobile phase. Commonly used mobile phases are nitrogen, helium 
and argon. The most commonly used detector type is the FID. Due to the volatility 
of organic solvents, GC is commonly used to identify and quantify the presence of 
residual solvents, such as acetone and EtOH, in PET radiopharmaceutical 
preparations. (Blumberg, 2012, Ph. Eur., 2013, Lodi and Boschi, 2017)   
 
Figure 15.  GC system. (Blumberg, 2012) 
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2.2.5 Good manufacturing practice 
A comprehensively designed and correctly implemented quality assurance (QA) 
system is of utmost importance in order to achieve the quality objectives. QA 
system is necessary to ensure that the safety and quality of 68Ga-labeled PET 
radiopharmaceuticals are adequate for the intended use. All instruments, equipment 
and technologies that may affect the quality of the product should undergo proper 
qualification protocols. Written and approved protocols specifying the acceptance 
criteria, critical steps and qualification procedure should be established. (Boschi et 
al., 2013) 
The aim of pharmaceutical GMP is to ensure the delivery of a consistently 
high-quality product that is appropriate for its intended use. The product also has to 
meet the specifications of its marketing authorization. FDA has released the cGMP 
requirements and guidance documents for PET drug products in 2005. The cGMP 
regulations are the minimum set of requirements for a facility to develop agents for 
commercial use. (Chi et al., 2014, Ballinger and Koziorowski, 2017) 
The main components of GMP are personnel, procedures and documentation, 
as well as facilities and equipment. All these are governed by a quality 
management system. Personnel must be adequately trained in any procedures they 
carry out. The training record must indicate that the member of staff has read the 
Standard operating procedure (SOP) and has demonstrated competence with 
evidence of a certain number of monitored activities. Persons who perform aseptic 
procedures must undergo periodic revalidation of their competence. The authorities 
and responsibilities at each level of staff must be specified. (Ballinger and 
Koziorowski, 2017)  
There has to be a person designated as production manager, or sometimes 
called responsible person. This person is responsible for the routine operation of 
the facility. Production manager ensures that the PET radiopharmaceuticals are 
produced accordintg to the GMP standard (Ballinger and Koziorowski, 2017)  
All SOPs must be written down, approved and reviewed at regular intervals. 
QA results must include evidence that the analytical equipment has been properly 
calibrated. The quality of starting materials is one of the underpinning features of 
GMP. Precursors must be obtained from approved vendors. There must be a 
process for inspecting or auditing vendors. All chemicals that remain in the final 
formulation of the PET radiopharmaceutical must be obtained from certified 
pharmaceutical suppliers, and active pharmaceutical ingredients must be obtained 
from a certified GMP source. Peptides derivatized with a suitable chelator for 68Ga 
must be certified to meet the requirements described in the relevant 
pharmacopoeial monograph, or in the absence of such a monograph, a monograph 
of the manufacturer approved by pharmaceutical authorities. Several commonly 
used peptides are commercially available in GMP quality with a certificate of 
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analysis. However, their cost is relatively high and they are not readily available in 
all countries. In the future, an increasing number of peptides with potential as 
precursors for 68Ga-labeled PET radiopharmaceuticals will come commercially 
available with a GMP certificate but some time may still be required. (Decristoforo 
et al., 2012, Ballinger and Koziorowski, 2017)  
The design and construction of facilities must afford a clean environment. 
Surfaces must be impervious and able to withstand regular cleaning. Proper 
operation of the facility must be documented by routine environmental and 
microbiological monitoring. Generally, radiosynthesis can be carried out in a Grade 
C environment. However, sterile filtration and dispensing must be carried out in a 
Grade A environment. These are generally achieved with a hot cell, laminar airflow 
cabinet or pharmaceutical isolator. All equipment must be kept in good working 
order with regular checks of performance and records of maintenance undertaken. 
(Ballinger and Koziorowski, 2017) 
The application of GMP to the production of PET radiopharmaceuticals has 
two separate challenges. The first challenge is related to the short half-lives of most 
radionuclides used in PET and, thus, the QC of these PET radiopharmaceuticals. 
The second challenge is related to the small-scale production. There should be 
clear segregation of responsibilities for production and QC. In addition, there 
should be independent release. Small-scale production of a range of products is 
carried out with a small number of automated synthesis units. In the past, this often 
involved reusable apparatus. Accordingly, there had to be a validated cleaning 
procedure between operations and a strict regime of segregation. Nowadays, sterile 
single-use cassettes are available for many products, which will make the 
production less risky and more reliable. Before a new product is introduced, there 
must be a number of validation runs with full analysis to establish the 
reproducibility and the quality of the product. (Ballinger and Koziorowski, 2017) 
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3 Aims 
The purpose of this study was to prepare GMP-grade 68Ga-labeled DOTA-Siglec-9 
available for clinical studies so that its suitability for PET imaging of inflammation 
in humans can be evaluated in the future. In vitro plasma protein binding studies 
were also performed to determine how [68Ga]Ga-DOTA-Siglec-9 translates 
between different species.  
In addition, the purpose of this study was to examine bis(phosphonate)-
induced bone accumulation of 68Ga-labeled NOTA-chelated bis(phosphonate)-
conjugated oligoribonucleotide. Biodistribution analysis of 68Ga-labeled 
oligoribonucleotide was performed using PET imaging. 
More specifically, the aims of the study were: 
1. To develop a fully automated protocol for producing GMP-grade 
[68Ga]Ga-DOTA-Siglec-9 for clinical studies. 
2. To study the stability and plasma protein binding of [68Ga]Ga-DOTA-
Siglec-9 in blood in vitro in five different species, including human. 
3. To prepare 68Ga-labeled NOTA-chelated bis(phosphonate)-conjugated 
anti-microRNA-21/microRNA-21 double helix. 
4. To study the bone accumulation, whole-body biodistribution and in vivo 
stability of 68Ga-labeled NOTA-chelated bis(phosphonate)-conjugated 
anti-microRNA-21/microRNA-21 double helix in healthy rats. 
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4 Materials and Methods 
All radiation work complied with the regulations of the Radiation and Nuclear 
Safety Authority of Finland. All animal experiments were approved by the 
National Animal Experiment Board in Finland and the Regional State 
Administrative Agency for Southern Finland. All animal experiments were 
conducted in accordance with the EU Directive on the protection of animals used 
for scientific purposes.  
4.1 68Ga-labeling and quality control (Subprojects 
I-III) 
4.1.1 Fractionated method for producing nonGMP-grade 
[68Ga]Ga-DOTA-Siglec-9 and related quality control 
(Subproject I) 
The synthesis was performed manually using the fractionated method. 68Ga was 
eluted with 0.1 M HCl (6 mL) from a 68Ge/68Ga generator (IGG100, 50 mCi (1850 
MBq); Eckert & Ziegler AG). Activity in MBq means the activity of parent isotope 
68Ge adsorbed on the column at the assay date of the generator. A fraction (0.7–1.0 
mL) with the highest RAC (280–360 MBq) was collected for subsequent use. The 
68Ga-eluate (0.5 mL) was mixed with HEPES (120 mg) to give a pH of 
approximately 4.1. The pH was measured using pH paper (Macherey Nagel). 
DOTA‐Siglec‐9 peptide (Peptide Specialty Laboratories GmbH, nonGMP-grade) 
was stored in freezer as a 1 mM solution dissolved in deionized water and was let 
to melt before use. DOTA‐Siglec‐9 peptide (3–35 nmol, 7.3–85 μg) was added and 
the reaction mixture was heated at 100 °C for 15 minutes. The pH was adjusted 
between 6–8 by adding 1 M NaOH (85 μL), if needed for injection. No further 
purification was performed. Total synthesis time was approximately 20 minutes, 
starting from the 68Ge/68Ga generator elution.  
RCP of nonGMP-grade [68Ga]Ga‐DOTA‐Siglec‐9 was determined using 
radio‐HPLC. The radio‐HPLC system consisted of LaChrom Instruments (Hitachi, 
Merck) and a Radiomatic 150TR radioisotope detector (Packard). C18 column 
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(Phenomenex Jupiter, 4.6 × 150 mm, 300Å, 5 μm) with the following HPLC 
conditions was used (Table 3.). Solvent A was water containing 0.1% 
trifluoroacetic acid (TFA) and solvent B was acetonitrile (ACN) containing 0.1% 
TFA. Flow rate was 1 mL/min and λ = 215 nm. 
Table 3.  Gradient for [68Ga]Ga‐DOTA‐Siglec‐9. 
t/min 0.1 % TFA/H2O (%) 0.1 % TFA/ACN (%) 
0.0 82 18 
2.0 82 18 
11.0 40 60 
15.0 82 18 
20.0 82 18 
4.1.2 GMP-grade [68Ga]Ga-DOTA-Siglec-9 (Subproject II) 
4.1.2.1 Radiosynthesis of GMP-grade [68Ga]Ga-DOTA-Siglec-9 using 
an acetone-based method and related quality control 
For the synthesis, the Modular-Lab PharmTracer radiosynthesis device and C4-
GA68-PP cassettes (Eckert & Ziegler AG) were used. In this acetone-based 
method, 68Ga was eluted from a 68Ge/68Ga generator (IGG100, 50 mCi (1850 
MBq); Eckert & Ziegler AG) using 0.1 M HCl (6 mL) and loaded onto a Strata-XC 
cation exchange cartridge. [68Ga]GaCl3 was passed through the Strata-XC cation 
exchange cartridge and acidified acetone (0.8 mL, containing 0.02 M HCl and 
3.25% water) was used to elute the radionuclide 68Ga from the Strata-XC into the 
reaction vial. The reaction vial contained GMP-grade DOTA-Siglec-9 precursor 
(80 μL, 40 μg, 16.5 nmol; ABX Advanced Biomedical Compounds GmbH), 0.2 M 
NaOAc buffer (2 mL, pH 4.0) and absolute EtOH (0.2 mL). The reaction mixture 
was kept at 65°C for 6 minutes (Figure 16.). Acetone was gradually evaporated 
into the waste vial via vent tubing during the reaction time.  
Reaction mixture was diluted using 4 mL physiological saline (0.9 mg/mL) and 
passed through a tC18 cartridge, which was washed twice with physiological saline 
(8 mL). Purified [68Ga]Ga-DOTA-Siglec-9 was eluted from the tC18 cartridge  into 
an end product vial with 70% EtOH (1.3 mL) via a filter (0.22 μm) and formulated 
into physiological saline (8.7 mL). Total synthesis time was 25 minutes, starting 
from the 68Ge/68Ga generator elution until the final product is ready for 
administration to human use. 
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The QC analysis of the GMP-grade [68Ga]Ga-DOTA-Siglec-9 consisted of 
chemical, physical and biological tests. Appearance of the final product was 
assessed by visual inspection, pH was measured using pH indicator strips 
(Macherey Nagel), radionuclidic identity was determined by measuring half-life 
using a dose calibrator, and radionuclidic purity was measured using a gamma 
counter. RCP, chemical purity and identity were analyzed using HPLC. RCP was 
also analyzed using TLC. Integrity of the sterile filter (0.22 µm) was controlled 
immediately after the radiosynthesis as a short-time test by a bubble-point test. 
Residual solvents (EtOH and acetone content) were measured post-release by GC-
FID using the standard protocols of Turku PET Centre GMP production unit. Also, 
radionuclidic purity was measured post-release after complete decay of 68Ga (t ≥ 48 
hours). Tests for sterility and bacterial endotoxins were carried out post-release.  
 
Figure 16. Radiosynthesis of GMP-grade [68Ga]Ga-DOTA-Siglec-9. 
The HPLC system (Shimadzu Prominence) was equipped with a radiodetector 
(Ortec, Model 266). C18 column (Phenomenex Kinetex, 4.6 × 75 mm, 100Å, 2.6 
μm) with the following HPLC conditions was used. Solvent A was water 
containing 0.16% TFA and solvent B was ACN containing 0.16% TFA. Linear 
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gradient from 18% B to 50% B over 12 minutes was in use. Flow rate was 1 
mL/min and λ = 220 nm. 
The eluent used for the instant thin-layer chromatography (iTLC) analyses was 
50% methanol in 1 M ammonium acetate buffer (pH 3.5) and iTLC silica gel (SG) 
paper (Varian Inc.) was used. A very small amount (0.5 µL) of the sample was 
applied to the iTLC-SG paper and the sample was developed (development path 
length 5–7 cm). The iTLC-SG paper was exposed against the imaging plate for a 
suitable time depending on the activity of the sample. The imaging plate was 
scanned with Fuji FLA-5100 Imager Reader (FUJIFILM Life Science) and Aida 
Image Analysis software (Elysia Raytest) was used. 
4.1.2.2 Radiosynthesis on nonGMP-grade 3’-[68Ga]Ga-NOTA-anti-
microRNA-21 and related quality control (Subproject III) 
The synthesis was performed manually using the fractionated method. 68Ga was 
eluted with 0.1 M HCl (6 mL) from a 68Ge/68Ga generator (IGG100, 50 mCi (1850 
MBq); Eckert & Ziegler AG). The radioactive elution peak was collected for the 
68Ga-labeling of nonGMP-grade 3′-NOTA-anti-microRNA-21. The 68Ga-eluate 
(0.5 mL) was mixed with NaOAc (18 mg) to give a 0.2 M solution with regard to 
NaOAc. The pH was adjusted to approximately 3.5 by adding 2 M HCl (47 μL). 
The pH was measured using pH paper (Macherey Nagel). 3′-NOTA-anti-
microRNA-21 was stored in freezer as a 0.7 mM solution dissolved in deionized 
water and was let to melt before use. 3′-NOTA-anti-microRNA-21 (20 nmol) was 
added and the reaction mixture was heated at 95°C for 10 minutes. No further 
purification was performed. Total synthesis time was approximately 20 minutes, 
starting from the 68Ge/68Ga generator elution. After 68Ga-labeling, 5′-alendronate-
conjugated microRNA-21 (none, 1, 2 or 4 equivalents) was added to the reaction 
mixture and the mixture was kept at r.t. for approximately 10 minutes to form the 
double helix (Figure 17.). 
RCP of both nonGMP-grade 3′-[68Ga]Ga-NOTA-anti-microRNA-21 and the 
68Ga-labeled double helix structure was determined using a radio‐HPLC. The 
radio-HPLC system consisted of LaChrom Instruments (Hitachi, Merck) and a 
Radiomatic 150TR radioisotope detector (Packard). C18 column (Waters 
µBondapak, 3.9 × 150 mm, 125Å, 10 μm) with the following HPLC conditions 
was used. Solvent A was ACN, solvent B was 50 mM ammonium acetate 
(NH4OAc) and solvent C was 50 mM phosphoric acid (H3PO4). Gradient elution 
from 0% to50 % ACN in 50 mM NH4OAc over 17 minutes, followed by washing 
with aqueous 50 mM H3PO4 was used.  Flow rate was 1 mL/min and λ = 220 nm. 
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Figure 17. Radiosynthesis of nonGMP-grade 3′-[68Ga]Ga-NOTA-anti-microRNA-21 and 
hybridization with 5′-alendronate-conjugated microRNA-21 to form the double helix. 
4.2 In vitro experiments 
4.2.1 Plasma protein binding and stability of nonGMP-grade 
[68Ga]Ga-DOTA-Siglec-9 (Subproject I) 
Venous blood samples from five different species were collected in heparinized 
tubes. These species were male Sprague‐Dawley rats (n = 3), healthy male 
C57BL/6N mice (n = 3), male New Zealand White rabbits (n = 3), female human 
subjects (n = 3) and a male Finnish landrace pig (n = 1). Plasma was separated 
from whole blood by centrifugation. Approximately 1 mL of plasma was 
transferred to an Eppendorf tube and approximately 0.8 MBq of nonGMP-grade 
[68Ga]Ga-DOTA-Siglec-9 was added and mixed. The tube was incubated at +37°C 
and three parallel sample series (80–100 μL) at 3, 30, 90, 145, 210 and 250 minutes 
time points were taken. ACN (1:1, v/v) was added to precipitate the plasma 
proteins. In addition, 10% sulfosalicylic acid (1:1, v/v) was used to precipitate the 
plasma proteins in order to compare the results (at 90 minutes time point, 
unpublished material). The mixtures were vortexed and centrifuged (4 minutes, 
14,500 rpm). To measure the plasma protein binding, the tubes were counted in a 
gamma counter (1480 Wizard 3″ gamma counter; PerkinElmer/Wallac). After that, 
the supernatant and precipitate were separated and counted in the gamma counter.  
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An aliquot of the supernatant was analyzed for tracer stability. The time points 
for the analyses were 3, 30, 90, 145, 210 and 250 minutes. The aliquot was diluted 
with 0.1% TFA/H2O and analyzed by radio-HPLC. The radio‐HPLC system 
consisted of LaChrom Instruments (Hitachi, Merck) and a Radiomatic 150TR 
radioisotope detector (Packard). C18 column (Phenomenex Jupiter, 10 × 250 mm, 
300Å, 5 μm) with the following HPLC conditions was used (Table 4.). Solvent A 
was 0.1% TFA/H2O and solvent B was 0.1% TFA/ACN. Flow rate was 5 mL/min 
and λ = 215 nm. 
Table 4.  Gradient used for analyzinf the stability of [68Ga]Ga-DOTA-Siglec-9  (unpublished 
material). 
t/min 0.1 % TFA/H2O (%) 0.1 % TFA/ACN (%) 
0.0 82 18 
2.0 82 18 
11.0 40 60 
14.0 40 60 
15.0 82 18 
20.0 82 18 
4.2.2 Plasma protein binding and stability of nonGMP-grade 
68Ga-labeled oligoribonucleotide (Subproject III) 
Approximately 0.5 MBq of nonGMP-grade 3′-[68Ga]Ga-NOTA-anti-microRNA-21 
or 3′-[68Ga]Ga-NOTA-anti-microRNA-21 + 1, 2 or 4 equivalents of 5′-alendronate-
conjugated microRNA-21 was added to an Eppendorf tube containing rat’s plasma 
(approximately 1 mL) and mixed. The tube was incubated at +37°C and three 
parallel sample series (100 μL) at 10, 30 and 60 minutes time points were taken. 
ACN (1:1, v/v) was added to precipitate the plasma proteins. The mixtures were 
vortexed and centrifuged (4 minutes, 14,500 rpm). The tubes were counted in a 
gamma counter (1480 Wizard 3″ gamma counter; PerkinElmer/Wallac), and the 
supernatant and precipitate were separated and counted in the gamma counter to 
measure plasma protein binding (unpublished material). 
An aliquot of the supernatant was analyzed for stability (unpublished 
material). The aliquot was diluted using 50 mM NH4OAc and analyzed by radio-
HPLC. C18 column (Waters µBondapak, 7.8 × 300 mm, 125Å, 10 μm) with the 
following HPLC conditions was used. Flow rate was 5 mL/min and λ = 260 nm. 
Solvent A was 50 mM NH4OAc, solvent B was ACN and solvent C was 50 mM 
H3PO4. Two slightly different gradients were used (Table 5. and Table 6.). 
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Table 5.  Gradient 1 used for analyzing the stability of 3′-[68Ga]Ga-NOTA-anti-microRNA-21 
(unpublished material). 
t/min 50 mM NH4OAc (%) ACN (%) 50 mM H3PO4 (%) 
0.0 100 0 0 
17.0 50 50 0 
18.0 0 0 100 
25.0 0 0 100 
27.0 100 0 0 
30.0 100 0 0 
Table 6.  Gradient 2 used for analyzing stability of 3′-[68Ga]Ga-NOTA-anti-microRNA-21 + 1, 2 
or 4 equivalents of 5′-alendronate-conjugated microRNA-21. 
t/min 50 mM NH4OAc (%) ACN (%) 50 mM H3PO4 (%) 
0.0 100 0 0 
11.0 50 50 0 
12.0 0 0 100 
16.0 0 0 100 
18.0 100 0 0 
20.0 100 0 0 
 
Stability of the nonGMP-grade 68Ga-labeled oligoribonucleotide at r.t. was also 
studied (unpublished material). NonGMP-grade 3′-[68Ga]Ga-NOTA-anti-
microRNA-21 or 3′-[68Ga]Ga-NOTA-anti-microRNA-21 + 1, 2 or 4 equivalents of 
5′-alendronate-conjugated microRNA-21 was kept at r.t. Aliquots (1 µL) were 
taken and analyzed at 0, 60, 120 and 180 minutes time points. C18 C18 column 
(Waters µBondapak, 7.8 × 300 mm, 125Å, 10 μm) with the following HPLC 
conditions was used. Solvent A was 50 mM NH4OAc, solvent B was ACN and 
solvent C was 50 mM H3PO4. Flow rate was 5 mL/min and λ = 260 nm. Three 
slightly different gradients were used (Table 5., Table 6. and Table 7.).  
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Table 7.  Gradient 3 used for analyzing the stability of 3′-[68Ga]Ga-NOTA-anti-microRNA-21 + 1 
equivalent of 5′-alendronate-conjugated microRNA-21. 
t/min 50 mM NH4OAc (%) ACN (%) 50 mM H3PO4 (%) 
0.0 100 0 0 
25.0 50 50 0 
26.0 0 0 100 
32.0 0 0 100 
33.5 100 0 0 
35.0 100 0 0 
4.3 In vivo studies 
4.3.1 In vivo imaging with nonGMP-grade 68Ga-labeled 
oligoribonucleotide (Subproject III) 
Mature and healthy male Sprague-Dawley rats (weight 441 ± 41 g, n = 4 per 
experiment) were anesthetized with isoflurane. 3′-[68Ga]Ga-NOTA-anti-
microRNA-21 or 3′-[68Ga]Ga-NOTA-anti-microRNA-21 + 1, 2 or 4 equivalents of 
5′-alendronate-conjugated microRNA-21 were i.v. injected via tail vein (25 ± 1.5 
MBq (6.4 ± 0.47 nmol)). The concentration of oligoribonucleotide in blood 
circulation immediately after the injection was 0.23 ± 0.037 μM based on the 
estimated total volume of blood.  
In vivo imaging and the whole-body distribution kinetics of i.v. administered 
radioactivity were evaluated using a high-resolution research tomograph PET 
camera (Siemens Medical Solutions). Two rats were imaged at the same time. Rats 
were kept on a warm pallet during the imaging procedure. Data acquired for 60 
minutes in a list mode, starting at the same as the injection, were iteratively 
reconstructed with the ordered-subsets expectation maximization 3D (OSEM3D) 
algorithm. Quantitative analysis was performed by defining regions of interest 
(ROI) in several organs (heart, kidney cortex, kidney medulla, knees, liver and 
urinary bladder) with Carimas software version 2.9 (Turku PET Centre). The 
average RAC in the ROI (kBq/mL) was used for further analyses. The uptake was 
reported as standardized uptake value (SUV) and time-radioactivity curves (TACs). 
SUV was calculated as the RAC of the ROI divided by the relative injected 
radioactivity expressed per animal bodyweight. Also the radioactivity remaining in 
the injection site (tail) was compensated. 
In addition, the bone uptake of 68Ga-labeled oligoribonucleotide was studied in 
more detail using PET/CT camera. Four male, small Sprague-Dawley rats were 
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PET/CT imaged with a dedicated small animal scanner (Inveon Multimodality, 
Siemens Medical Solutions). Prior to PET, CT was performed for attenuation 
correction and anatomical reference. After that, rats (weight 85 ± 12 g) were i.v. 
injected with nonGMP-grade 68Ga-labeled oligoribonucleotide (22 ± 0.4 MBq, n = 
1 per compound). The PET data acquired for 60 minutes was reconstructed with 
OSEM3D. PET/CT images were visually observed with Inveon Research 
Workplace 4.1 software (Siemens Medical Solutions). 
4.3.2 Blood and urine samples (Subproject III) 
Rats were i.v. injected with nonGMP-grade 3′-[68Ga]Ga-NOTA-anti-microRNA-21 
or 3′-[68Ga]Ga-NOTA-anti-microRNA-21 + 1, 2 or 4 equivalents of 5′-alendronate-
conjugated microRNA-21. Blood and urine samples were obtained after 60 minutes 
PET imaging. ACN (1:1, v/v) was added to precipitate the plasma proteins. The 
mixtures were vortexed and centrifuged (4 minutes, 14,500 rpm). The supernatant 
and precipitate were separated and an aliquot of the supernatant was analyzed for 
the stability. The aliquot was diluted using 50 mM NH4OAc and analyzed by radio-
HPLC. C18 column (Waters µBondapak, 7.8 × 300 mm, 125Å, 10 μm) was used, 
flow rate was 5 mL/min and λ = 260 nm. Solvent A was 50 mM NH4OAc, solvent 
B was ACN and solvent C was 50 mM H3PO4. Two slightly different gradients 
were used (Table 5. and Table 6.). 
Urine samples were diluted using 50 mM NH4OAc and analyzed by radio-
HPLC. C18 column (Waters µBondapak, 7.8 × 300 mm, 125Å, 10 μm) was used, 
flow rate was 5 mL/min and λ = 260 nm. Solvent A was 50 mM NH4OAc, solvent 
B was ACN and solvent C was 50 mM H3PO4. Two slightly different gradients 
were used (Table 5. and Table 6.). 
4.4 Ex vivo biodistribution experiments (Subproject 
III) 
Ex vivo biodistribution was determined after the PET imaging. Rats were 
euthanized after PET imaging and the RAC in excised organs and tissues was 
measured with a gamma counter (1480 Wizard 3″ gamma counter; 
PerkinElmer/Wallac). Measured radioactivity was corrected for decay, weight of 
the organs, and animal and background radioactivity. Measured radioactivity was 
expressed as SUV. Examined organs and tissues were bone, bone marrow, heart, 
kidneys, liver, lungs, pancreas, plasma, salivary glands, skin, spleen and urine. 
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4.5 UV-melting profile analysis of 3’-NOTA-anti-
microRNA-21/5’-bis(phosphonate)-microRNA-
21 double helix (Subproject III)  
UV-melting profile analysis of 3′-NOTA-anti-micro-RNA-21/5′-bis(phosphonate)-
microRNA-21 double helix was performed. Melting curves were measured at 260 
nm on a UV-VIS light spectrometer equipped with a multiple cell holder and a 
Peltier temperature controller. The temperature was changed at a rate of 0.5 
°C/min. The measurements were performed in aqueous solutions of 2 μM of 3′-
NOTA-anti-microRNA-21 and 5′-alendronate-conjugated microRNA-21, with 10 
mM sodium cacodylate and 0.1 M NaCl (pH 7.0) and of 1 μM of 3′-
[69/71Ga]69/71Ga-NOTA-anti-microRNA-21 and 5′-alendronate-conjugated 
microRNA-21, with 0.2 M NaOAc and 0.05 M NaCl (pH 9.0) (68Ga-labeling 
conditions mimicked). 
4.6 Statistical analyses 
All data are expressed as the mean ± standard deviation (SD) with two significant 
figures. Different tissues from the same subject were compared using Student’s t-
test for paired data and unpaired Student’s t-test for comparison between two study 
groups. P-values less than 0.05 were considered statistically significant. 
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5 Results 
5.1 Radiosynthesis and quality control 
(Subprojects I-III) 
5.1.1 NonGMP-grade [68Ga]Ga-DOTA-Siglec-9 using 
fractionated method (Subproject I) 
Fractionated method was used for producing nonGMP-grade [68Ga]Ga-DOTA-
Siglec-9. QC was done using radio-HPLC. The reaction mixture was ≥ 95% 
radiochemically pure. Molar activity was up to 70 MBq/nmol (63 ± 7 MBq/nmol, 
when the lowest amount of precursor (3 nmol) was used in the synthesis). In this 
context, molar activity is a theoretical value using all analogues of DOTA-Siglec-9 
independent of binding or not and assuming that all of the peptide used will end up 
in the product. RCY of the radiosynthesis was 71 ± 2% (non decay-corrected). 
Overall yield (the yield of the radiosynthesis × the radioactivity coming out of the 
68Ge/68Ga generator) was 40 ± 2% (n = 4). Retention time of nonGMP-grade 
[68Ga]Ga-DOTA-Siglec-9 was approximately 9.8 minutes. 
5.1.2 GMP-grade [68Ga]Ga-DOTA-Siglec-9 using acetone-
based (Subproject II) 
GMP-grade [68Ga]Ga-DOTA-Siglec-9 was produced using acetone-based method. 
Radio-HPLC and radio-TLC were used for QC analyses (Figure 18.). Using radio-
HPLC, RCP was > 95% (n = 5) and also chemical purity was > 95%. RCP was also 
confirmed by iTLC. RCP was > 95% (n = 3). It was observed that [68Ga]Ga-
DOTA-Siglec-9 migrated clearly up from the baseline on iTLC plates. The decay-
corrected RCY was 90 ± 3% (n = 3). As an example, in one of the produced 
batches, the radioactivity of the end product was 1106 MBq in 10 mL of 
physiological saline at EOS and molar activity was 67 GBq/µmol. 
The amounts of radioactivity stuck on the reaction vial and tC18 cartridge were 
found to be insignificant (< 2%). The automated process was programmed to wash 
the tC18 cartridge twice during the purification process in order to make sure that 
the acetone content in the end product would remain under the limit required for 
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human use (0.5%). In randomly selected batches (n = 3), GC using the standard 
protocols of the Turku PET Centre GMP production unit revealed no detectable 
amount of acetone (0.0%) in the final product. In addition, the EtOH content (8.8 ± 
0.1%, n = 3) was observed to be under the limit (10%) as well. The product was 
stable at r.t. for 4 hours. Longer times were not tested. 
The total content of DOTA-Siglec-9 peptide in each batch was below the limit 
of 4.1 μg/mL. [68Ga]Ga-DOTA-Siglec-9 is a new PET radiopharmaceutical. 
Because this tracer has not been studied in humans previously, it was critical to set 
a dose limit in terms of mass quantity (Koziorowski et al., 2016). In addition, 
single-dose acute toxicity studies in rats have been performed and no adverse 
effects have been observed (unpublished data). The concentration limit of the final 
product was set at 4.1 μg/mL in a total volume of 10 mL. This concentration limit 
was derived from the limit of 68Ga-labeled bombesin antagonist [68Ga]Ga-DOTA-
4-amino-1-carboxymethylpiperidine-D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-
NH2. This tracer has been developed in Turku PET Centre earlier (Roivainen et al., 
2013). 
 
Figure 18.  (A) Radiochromatogram of GMP-grade [68Ga]Ga-DOTA-Siglec-9.  (B) Photostimulated 
luminescence (PSL) imaging of the iTLC plate (the retention factor of [68Ga]Ga-DOTA-
Siglec-9 was 0.57 during 35 minutes of development) and iTLC profile of [68Ga]Ga-
DOTA-Siglec-9. 
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Figure 19.  HPLC-chromatograms. (A) The UV peak of GMP-grade [68Ga]Ga-DOTA-Siglec-9 . The 
small size of the peak is due to the high molar activity at EOS. (B) UV detection of a 
control sample. The radiosynthesis is performed without addition of precursor DOTA-
Siglec-9. (C) UV detection of DOTA-Siglec-9 (reference sample). 
A couple of minor peaks at a retention time of approximately 4 minutes were 
observed in every produced batch in the UV trace of the HPLC chromatograms 
(Figure 19.). These minor peaks were not observed in the blank or reference 
samples. A control radiosynthesis was performed without the precursor compound 
DOTA-Siglec-9. Otherwise the exactly same protocol as for producing GMP-grade 
[68Ga]Ga-DOTA-Siglec-9 was used. The “end product” solution was subjected to 
HPLC analysis and these minor peaks were observed to appear at the expected 
retention times. Thus, it was confirmed that these impurity peaks were derived 
from the radiosynthesis system rather than from the peptide itself. 
Different concentrations of TFA in the HPLC solvents were tested before 
ending up using 0.16% TFA. 0.1% and 0.2% TFA in HPLC solvents were used to 
find the optimal concentration. C18 column (Phenomenex Kinetex, 4.6 × 75 mm, 
100Å, 2.6 μm) with the following HPLC conditions was used (Table 8.). Solvent A 
was water containing 0.1% or 0.2% TFA and solvent B was ACN containing 0.1% 
or 0.2% TFA. Flow rate was 1 mL/min. Retention time of GMP-grade [68Ga]Ga-
DOTA-Siglec-9 was 4.5 minutes when using the above mentioned concentrations 
of TFA. Using linear gradient and 0.16% TFA (cf. section 4.1.2.3), the retention 
time of GMP-grade [68Ga]Ga-DOTA-Siglec-9 was approximately 6.3 minutes. 
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Table 8.  Gradient used for analyzing GMP-grade [68Ga]Ga-DOTA-Siglec-9 using 0.1% and 
0.2% TFA. 
t/min TFA/H2O (%) TFA/ACN (%) 
0.0 82 18 
1.0 82 18 
5.5 40 60 
7.0 40 60 
7.5 82 18 
10.0 82 18 
 
During the variation tests for the HPLC methods, it was observed that the 
concentration of TFA in the solvents plays an important role in the analysis. A 
typical TFA concentration for HPLC analysis of peptide-based PET 
radiopharmaceuticals is 0.1% by volume. However, this was not sufficient for the 
analysis of GMP-grade [68Ga]Ga-DOTA-Siglec-9. When a higher TFA 
concentration (0.16% or 0.2%) was used, the peaks were sharp without tailing 
(Figure 20.).  
 
Figure 20.  HPLC analysis of GMP-grade [68Ga]Ga-DOTA-Siglec-9 with different concentrations of 
TFA in the HPLC solvents. (A) [68Ga]Ga-DOTA-Siglec-9 analysis, 0.1% TFA. (B) 
[68Ga]Ga-DOTA-Siglec-9 analysis, 0.2% TFA. 
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5.1.2.1 Sticking problem and problem solving 
Table 9.  Troubleshooting table. 
Place and initial loss 
of the radioactivity 
 
Options  
 
Solution 
Waste vial: unreacted 
68Ga ~ 20 % - 
Acetone-based method (acidified 
acetone for elution of the cartridge)  
Reaction vial: ~ 20 % Lower temperature (50°C) 
Shorter reaction time (5 minutes) 
Decreased concentration of NaOAc 
buffer (0.08 M) 
Reduced concentration of NaCl for 
elution of SCX (from 5 M to 1.5 M) 
Acetone-based method 
tC18 cartridge: ~ 30 % Increased concentration of EtOH  
Absolute EtOH  
Different cartridges (C18, C8, 
hydrophilic–lipophilic balance) 
Acetone-based method 
Injected radioactivity 
stuck at the head of the 
HPLC column 
Modification of flow rate 
Properties of column (C4, C8, well-
blocked silanols) 
Properties of solvent 
Addition of non-radiolabeled 
DOTA-Siglec-9 
Acetone-based method 
 
During the tests performed, it was observed that the decay-corrected RCY was 
approximately 30%. The unreacted 68Ga was found in the waste vial and significant 
amount of radioactivity also remained in the reaction vial and on the tC18 cartridge 
(Table 9.). Several options to overcome the sticking problem were tried (Table 9.). 
1.5 M NaCl was found to be the minimum applicable concentration for elution of 
an SCX cartridge in an experimental setting. After these modifications, it was 
observed that less radioactivity stuck to SPE cartridges and reaction vials. 
However, at reduced temperatures and with shortened reaction times the levels of 
free 68Ga increased in the waste vial and the labeling efficiency weakened.  
The injected radioactivity stuck at the head of the HPLC column. To solve this 
problem, the HPLC methods were modified in many different ways (Table 9). 
HPLC columns (e.g. XBridge Shield RP18) with well-blocked silanols were tested 
to exclude the possibility that sticking was caused by the net positive charge of the 
end product.  
Also, varying amounts (60–120 µg/mL) of non-radiolabeled GMP-grade 
precursor compound DOTA-Siglec-9 were added to the HPLC samples of 68Ga-labeled 
end product (Table 9.). By doing so, the radioactivity exited of the HPLC columns. The 
quantity of analyte is tiny in terms of mass or molarity, a known phenomenon for PET 
radiopharmaceuticals. This may partially explain why an addition of a “carrier” can 
help analytes travel through the materials packed into HPLC columns. 
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The sticking problem was caused by conformational changes in the peptide 
structure during radiosynthesis. The combination of high temperature, long 
reaction time and high salt content denatured the DOTA-Siglec-9 peptide. In brief, 
the acetone-based method (cf. section 4.1.2.1) means that acidified acetone was 
used to elute 68Ga from the cation exchange cartridge, 0.2 M NaOAc buffer was 
used in the reaction vial and the reaction mixture was kept at 65°C for 6 minutes. 
Thus, lower temperature, shorter reaction time and decreased concentration of 
NaOAc buffer solved the above mentioned problems. 
5.1.3 NonGMP-grade 3’-[68Ga]Ga-NOTA-anti-microRNA-21 
using fractionated method (Subproject III) 
NonGMP-grade 3′-[68Ga]Ga-NOTA-anti-microRNA-21 was produced successfully 
using fractionated method. QC was done using radio-HPLC. RCP of 3′-[68Ga]Ga-
NOTA-anti-microRNA-21 was determined to be 94 ± 2%, molar activity  was 6.3 
± 0.6 GBq/μmol at EOS. Retention time of nonGMP-grade 3′-[68Ga]Ga-NOTA-
anti-microRNA-21 was approximately 6.3 minutes (Figure 21., chromatogram A). 
Formation of the 68Ga-labeled double helix was verified using radio-HPLC (Figure 
21., chromatograms B and C). 
 
Figure 21. Radiochromatograms of (A) nonGMP-grade 3′-[68Ga]Ga-NOTA-anti-microRNA-21 
alone, (B) nonGMP-grade 3′-[68Ga]Ga-NOTA-anti-microRNA-21 + 1 equivalent of 5′-
alendronate-conjugated microRNA-21 and (C) a co injection of the mixed samples 
(A+B, 1:1).  
5.2 In vitro experiments 
5.2.1 Plasma protein binding of nonGMP-grade [68Ga]Ga-
DOTA-Siglec-9 (Subproject I) 
In vitro experiments using blood from five different species were performed to 
determine how [68Ga]Ga-DOTA-Siglec-9 translates between species. It was 
Meeri Käkelä 
 80 
observed that there are some species-specific differences (Figure 22.). At the first 
time point, 3 minutes, the highest in vitro plasma protein binding of [68Ga]Ga-
DOTA-Siglec-9 was seen in rats (34%) and mice (35%). The lowest was seen in 
pigs (22%). Fast initial binding was observed in all species and a very slow 
increase over time was seen for pigs (from 22% to 25%) and rats (from 34% to 
41%) from 3 minutes to 250 minutes. Mice (fom 35% to 55%) and humans (from 
27% to 46%) had the highest relative increase in the plasma protein binding over 
time with an increase of approximately 60% from 3 minutes to 250 minutes. 
Rabbits (from 25% to 36%) had an increase of approximately 40% from 3 minutes 
to 250 minutes. 
 
Figure 22. In vitro plasma protein binding of [68Ga]Ga-DOTA-Siglec-9 as a function of time in five 
different species. 
5.2.2 Stability of nonGMP-grade [68Ga]Ga-DOTA-Siglec-9 
(Subproject I) 
The in vitro stability of [68Ga]Ga-DOTA-Siglec-9 in human, mouse, pig, rabbit and 
rat plasma was examined at the same time points as the relative plasma protein 
binding (Table 10.). It was observed that, in plasma in vitro, the [68Ga]Ga-DOTA-
Siglec-9 stability depended heavily on which species the plasma came from (Figure 
23.). For example, after 90 minutes of incubation, over 50% of the [68Ga]Ga-
DOTA-Siglec-9 had degraded in rabbit’s plasma, whereas little degradation 
occurred in pig’s plasma (only 5%). In rabbit’s plasma, the fast degradation 
became even more pronounced at later time points and only approximately 30% of 
the radioactivity of [68Ga]Ga-DOTA-Siglec-9 was intact after 250 minutes of in 
vitro incubation. According to the results, the in vitro plasma stabilities of 
[68Ga]Ga-DOTA-Siglec-9 in the other three species (human, mouse and rat) were 
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in between those for pigs and rabbits. After 90 minutes of incubation, more than 
80% of [68Ga]Ga-DOTA-Siglec-9 was still intact in human’s plasma. 
 
Figure 23. In vitro stability of [68Ga]Ga-DOTA-Siglec-9 in animals and human plasma as a 
function of time. 
Table 10. In vitro plasma protein binding (%) of [68Ga]Ga-DOTA-Siglec-9 radioactivity.  
t (min) 
Male sprague-
dawley rats 
(n=3) 
Male 
C57B1N/6N 
mouse (n=3) 
Male New 
Zealand White 
rabbit (n=3) 
Female 
human (n=3) 
Male Finnish 
landrace pig (n=1) 
Commercial porcine 
serum (n=3) 
3 34.1 ± 8.2 35.1 ± 1.1 25.5 ± 6.0 27.1 ± 2.0 22.0 ± 3.5 
30 36.1 ± 6.9 32.8 ± 3.5 27.8 ± 3.7 29.9 ± 0.2 24.4 ± 2.9 
90 38.5 ± 1.6 41.0 ± 2.3 32.0 ± 2.5 33.4 ± 2.2 24.7 ± 2.1 
145 37.2 ± 2.6 41.0 ± 1.4 30.4 ± 3.1 33.0 ± 4.5 24.3 ± 2.5 
210 39.9 ± 3.5 44.7 ± 2.1 32.0 ± 2.1 36.1 ± 5.9 25.6 ± 4.2 
250 41.1 ± 1.3 55.4 ± 4.0 35.6 ± 3.6 45.6 ± 5.5 24.1 ± 0.1* 
Results are expressed as % (mean ± SD). 
*Only two measurements were taken to determine the mean and SD at 250 minute time point. 
5.2.3 Plasma protein binding of 68Ga-labeled 
oligoribonucleotide (Subproject III) 
According to the radio-HPLC analysis, the in vitro plasma protein binding of 
nonGMP-grade 3′-[68Ga]Ga-NOTA-anti-microRNA-21 alone was observed to be 
clearly lower as compared with the 68Ga-labeled double helix structure. Plasma protein 
binding measures at 10, 30 and 60 minutes time points are presented in Table 11.  
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Table 11.  Plasma protein binding based on 68Ga radioactivity measurements (mean ± SD, n = 3) 
Oligoribonucleotide 
Protein binding (%) 
in vitro, rat plasma 
+37°C / 10 min* 
Protein binding (%) 
in vitro, rat plasma 
+37°C / 30 min* 
Protein binding (%) 
in vitro, rat plasma 
+37°C / 60 min 
1 40 ± 3.1 35 ± 5.4 31 ± 2.1 
1 + 1 equivalent of 2 74 ± 0.8 74 ± 1.8 72 ± 2.3 
1 + 2 equivalents of 2 77 ± 1.1 79 ± 4.4 80 ± 4.4 
1 + 4 equivalents of 2 74 ± 0.1 77 ± 1.2 76 ± 0.5 
1 is nonGMP-grade 3′-[68Ga]Ga-NOTA-anti-microRNA-21 
2 is 5′-alendronate-conjugated microRNA-21 
* unpublished data 
5.2.4 Stability of nonGMP-grade 68Ga-labeled 
oligoribonucleotide (Subproject III) 
According to the radio-HPLC analysis, the in vitro stability of nonGMP-grade 3′-
[68Ga]Ga-NOTA-anti-microRNA-21 alone at r.t. (Figure 25.) was observed to be 
weaker when compared with the 68Ga-labeled double helix structure. Stability 
measures at 1, 2 and 3 hours time points are presented in Table 12.  
Table 12. Stability based on 68Ga radioactivity measurement (n = 1) 
Oligoribonucleotide 
Stability (%) in vitro  
r.t. / 1 h* 
Stability (%) in vitro 
r.t. / 2 h* 
Stability (%) in vitro 
r.t. / 3 h 
1 76 79 77 
1 + 1 equivalent of 2 92 93 91 
1 + 2 equivalents of 2 92 93 93 
1 + 4 equivalents of 2 90 91 90 
1 is nonGMP-grade 3′-[68Ga]Ga-NOTA-anti-microRNA-21 
2 is 5′-alendronate-conjugated microRNA-21 
* unpublished data 
According to the radio-HPLC analysis, the in vitro stability of nonGMP-grade 3′-
[68Ga]Ga-NOTA-anti-microRNA-21 alone in rat’s plasma (Figure 24.) was 
observed to be higher when compared with the 68Ga-labeled double helix structure. 
Stability measures at 10, 30 and 60 minutes time points are presented in Table 13. 
Broadly speaking, the stability results in both conditions (in rat’s plasma and at r.t.) 
were quite constant between different time points.  
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Table 13.  Stability in rat’s plasma based on 68Ga radioactivity measurements (mean ± SD, n = 3) 
 
 
Oligoribonucleotide 
Stability (%) in vitro, 
rat plasma 
+37°C / 10 min* 
Stability (%) in vitro, 
rat plasma 
+37°C / 30 min* 
Stability (%) in vitro, 
rat plasma 
+37°C / 60 min 
1 98 ± 0.2 98 ± 0.4 98 ± 0.4 
1 + 1 equivalent of 2 84 ± 7.5 87 ± 2.3 89 ± 3.2 
1 + 2 equivalents of 2 83 ± 10.5 89 ± 2.9 87 ± 3.4 
1 + 4 equivalents of 2 91 ± 2.6 92 ± 0.2 90 ± 0.8 
1 is nonGMP-grade 3′-[68Ga]Ga-NOTA-anti-microRNA-21 
2 is 5′-alendronate-conjugated microRNA-21 
* unpublished data 
 
Figure 24. Radio-HPLC chromatograms of the in vitro stability experiments. (A) nonGMP-grade 
3′-[68Ga]Ga-NOTA-anti-microRNA-21 (retention time 9.65 min) incubated for 3 hours at 
r.t.; (B) nonGMP-grade 3′-[68Ga]Ga-NOTA-anti-microRNA-21 (retention time 9.53 min) 
incubated for 1 hour, rat plasma in vitro, + 37°C; (C) nonGMP-grade 3′-[68Ga]Ga-
NOTA-anti-microRNA-21 + 1 equivalent of 5′-alendronate-conjugated microRNA-21 
(retention time 6.22 min) incubated for 3 hours at r.t.; and (D) nonGMP-grade 3′-
[68Ga]Ga-NOTA-anti-microRNA-21 + 1 equivalent of 5′-alendronate-conjugated 
microRNA-21 (retention time 6.23 min) incubated for 1 hour, rat plasma in vitro, + 37 
°C. Gradient 1 (A–B) (Table 5.) and gradient 2 (C–D) (Table 6.) were used. 
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5.3 In vivo studies 
5.3.1 In vivo imaging with 68Ga-radiolabeled 
oligoribonucleotide (Subproject III) 
The administration of nonGMP-grade 3′-[68Ga]Ga-NOTA-anti-microRNA-21 with 
5′-alendronate-conjugated microRNA-21 changed the bone uptake remarkably as 
compared with nonGMP-grade 3′-[68Ga]Ga-NOTA-anti-microRNA-21 alone 
(Figures 25–27.). The increased radioactivity in knees is seen in whole-body 
coronal PET images (Figure 25.) and even more clearly in PET/CT images (Figure 
26.). The prolonged radioactivity (nonGMP-grade 3′-[68Ga]Ga-NOTA-anti-
microRNA-21 alone versus 3′-[68Ga]Ga-NOTA-anti-microRNA-21 + 1, 2 or 4 
equivalents of 5′-alendronate-conjugated microRNA-21) in knees can be observed 
in the TACs across the distribution (0–60 min, Figure 27.).  
 
Figure 25. Whole-body coronal PET images of healthy rats i.v. injected with 68Ga-labeled 
oligoribonucleotide. Images are summation from 50–60 minutes post injection and 
they are presented in the same colour scale. (A) nonGMP-grade 3′-[68Ga]Ga-NOTA-
anti-microRNA-21 alone; (B) nonGMP-grade 3′-[68Ga]Ga-NOTA-anti-microRNA-21 + 1 
equivalent of 5′-alendronate-conjugated microRNA-21; (C) nonGMP-grade 3′-
[68Ga]Ga-NOTA-anti-microRNA-21 + 2 equivalents of 5′-alendronate-conjugated 
microRNA-21; and (D) nonGMP-grade 3′-[68Ga]Ga-NOTA-anti-microRNA-21 + 4 
equivalents of 5′-alendronate-conjugated microRNA-21. 
Results 
 85 
 
Figure 26. PET/CT images of healthy rats i.v. injected with 68Ga-labeled oligoribonucleotide. 
Images are summation from 0–60 minutes post injection and they are presented in the 
same colour scale. (A) nonGMP-grade 3′-[68Ga]Ga-NOTA-anti-microRNA-21 alone; 
(B) nonGMP-grade 3′-[68Ga]Ga-NOTA-anti-microRNA-21 + 1 equivalent of 5′-
alendronate-conjugated microRNA-21; (C) nonGMP-grade 3′-[68Ga]Ga-NOTA-anti-
microRNA-21 + 2 equivalents of 5′-alendronate-conjugated microRNA-21; and (D) 
nonGMP-grade 3′-[68Ga]Ga-NOTA-anti-microRNA-21 + 4 equivalents of 5′-
alendronate-conjugated microRNA-21 (Bl = urinary bladder, Ep = epiphysis bone, Hr = 
heart, Kd = kidney, Lv = liver, Md = mandible bone, Mx = maxilla bone). 
 
Figure 27. TACs (RAC as a function of time) of the distribution kinetics of nonGMP-grade 68Ga-labeled 
oligoribonucleotide in rat’s knee (1[68Ga] = nonGMP-grade 3′-[68Ga]Ga-NOTA-anti-
microRNA-21, 2 = 5′-alendronate-conjugated microRNA-21, error bars denote SD, n = 4). 
5.3.2 Blood and urine samples (Subproject III) 
According to the radio-HPLC analysis of an aliquot taken from plasma 60 minutes 
after the i.v. administration, 11% of nonGMP-grade 3′-[68Ga]Ga-NOTA-anti-
microRNA-21 and 28% of nonGMP-grade 3′-[68Ga]Ga-NOTA-anti-microRNA-
21/2-duplex (with 1 equivalent of 5′-alendronate-conjugated microRNA-21) were 
still intact (Figure 28.). The corresponding values of the samples taken from urine 
Meeri Käkelä 
 86 
were 81% for nonGMP-grade 3′-[68Ga]Ga-NOTA-anti-microRNA-21 and 88% for 
nonGMP-grade 3′-[68Ga]Ga-NOTA-anti-microRNA-21/2-duplex (Figure 30.). In 
vivo stability results at 1 hour time point are presented in Table 14.  
Table 14.  Stability (%) in vivo based on 68Ga radioactivity measurement (n = 1). 
 
Oligoribonucleotide 
Stability (%) in vivo, 
rat plasma / 1 h 
Stability (%) in vivo, 
rat urine / 1 h 
1 11 81 
1 + 1 equivalent of 2 28 88 
1 + 2 equivalents of 2 18 84 
1 + 4 equivalents of 2 38 91 
1 is nonGMP-grade 3′-[68Ga]Ga-NOTA-anti-microRNA-21 
2 is 5′-alendronate-conjugated microRNA-21 
 
Figure 28. Radio-HPLC chromatograms of the in vivo stability experiments. (A) nonGMP-grade 3′-
[68Ga]Ga-NOTA-anti-microRNA-21 (retention time 9.64 min), 1 hour, rat’s plasma; (B) 
nonGMP-grade 3′-[68Ga]Ga-NOTA-anti-microRNA-21 (retention time 9.46 min), 1 hour, 
rat’s urine; (C) nonGMP-grade 3′-[68Ga]Ga-NOTA-anti-microRNA-21 + 1 equivalent of 5′-
alendronate-conjugated microRNA-21 (retention time 6.21 min), 1 hour, rat’s plasma; 
and (D) nonGMP-grade 3′-[68Ga]Ga-NOTA-anti-microRNA-21 + 1 equivalent of 5′-
alendronate-conjugated microRNA-21 (retention time 6.27 min), 1 hour, rat’s urine. 
Gradient 1 (A–B) (Table 5.) and gradient 2 (C–D) (Table 6.) were used. 
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5.4 Ex vivo biodistribution experiments (Subproject 
III) 
Observations obtained during PET studies were supported in a more detailed 
analysis of the ex vivo by gamma counting measurements of excised tissues (Figure 
29.). The separate tibia and bone marrow uptakes verified the increased (ca. 40%) 
tibia accumulation of nonGMP-grade 3′-[68Ga]Ga-NOTA-anti-microRNA-21/5′-
alendronate-conjugated microRNA-21/2-duplex, whereas nonGMP-grade 3′-
[68Ga]Ga-NOTA-anti-microRNA-21 alone accumulated to larger extent to bone 
marrow. The administration of nonGMP-grade 3′-[68Ga]Ga-NOTA-anti-
microRNA-21 without 5′-alendronate-conjugated microRNA-21 showed higher 
uptake in all other tissues studied: kidneys, liver, spleen, salivary glands, pancreas, 
lungs, heart and skin, in comparison with uptakes of nonGMP-grade 3′-[68Ga]Ga-
NOTA-anti-microRNA-21 with 5′-alendronate-conjugated microRNA-21. 
Additionally, the double helical administration decreased the radioactivity in 
plasma but increased the radioactivity excreted to urine.  
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Figure 29. RAC at 60 minutes after i.v. injection of nonGMP-grade 68Ga-oligoribonucleotide. 
Measured ex vivo by gamma counting of excised tissues of healthy rats (1[68Ga] = 
nonGMP-grade 3′-[68Ga]Ga-NOTA-anti-microRNA-21, 2 = 5′-alendronate-conjugated 
microRNA-21, error bars denote SD, n = 4). Bone = tibia. 
5.5 UV melting profile analysis of 68Ga-labeled 
double helix (Subproject III) 
UV-melting profile analysis was used to evaluate the thermal stability of the double 
helix between 3′-NOTA-anti-microRNA-21 and 5′-alendronate-conjugated 
microRNA-21. The melting curves were presented as normalized absorbance 
versus temperature profiles (Figure 30.). A mixture (Tm = 88°C, 3′-[69/71Ga]Ga-
NOTA-anti-micro-RNA-21 and 5′-alendronate-conjugated microRNA-21, 0.2 M 
NaOAc and 0.05 M NaCl) that mimics the 68Ga-labeling conditions was used and a 
relatively stable double helix was observed in this mixture. However, the stability 
of the duplex in vitro is not comparable to that in the bloodstream. 
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Figure 30. UV-melting profiles of the double helix. Conditions used: a) 2 µM of 3′-NOTA-anti-
microRNA-21 in 10 mM sodium cacodylate and 0.1 M NaCl (pH 7.0); b) 2 µM 3′-
[69/71Ga]Ga-NOTA-anti-microRNA-21 and 5′-alendronate-conjugated microRNA-21, 0.2 
M NaOAc and 0.05 M NaCl (pH 9.0). 
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6 Discussion 
6.1 Radiolabeling 
6.1.1 Fractionated method and 68Ga-radiolabeling 
In Subprojects I and III, fractionated method was used successfully for producing 
nonGMP-grade 68Ga-labeled tracers. The advantage of the fractionated method is 
that no organic solvent is required. Previously, the fractionated method has been 
used successfully for radiolabeling DOTA-peptides (Breeman et al., 2005, Ujula et 
al., 2009, Ahtinen et al., 2014, Virtanen et al., 2015) and NOTA-oligonucleotides 
(Kiviniemi et al., 2012, Mäkilä et al., 2014). 
The key point of this method is that the fraction with highest volume 
radioactivity is collected and buffered to an appropriate pH for radiolabeling (de 
Blois et al., 2011). Fractionated method is potentially effective but the drawback is 
that only a fraction of the eluted 68Ga radioactivity is used. This reduces the 
achievable molar activity of the final product (Mueller et al., 2012). In Subproject 
I, when radiolabeling nonGMP-grade [68Ga]Ga-DOTA-Siglec-9, the amount of 
peptide used was 3 nmol. Because of the small amount of peptide, the molar 
activity of the final nonGMP-grade [68Ga]Ga-DOTA-Siglec-9 was high despite of 
the application of the fractionation method.  
In Subproject III, 20 nmol of 3′-NOTA-chelated anti-microRNA-21 was used 
for 68Ga-labeling. Thus, molar activity of nonGMP-grade 3′-[68Ga]Ga-NOTA-anti-
microRNA-21 was rather low. Conditions used for the 68Ga-labeling of nonGMP-
grade 3′-NOTA-chelated anti-microRNA-21 had previously been optimized for 
oligonucleotides (Roivainen et al., 2004) and were only slightly modified here. To 
improve the molar activity, the labeling procedure needs still further optimization. 
Fractionated elution results in a ready-to-use eluate (de Blois et al., 2011). In 
Subprojects I and III, the eluate was used without any pre-purification. The major 
limitations for direct use of 68Ga for radiolabeling are 68Ge breakthrough, potential 
metal ion impurities, high proton concentration and large volume of generator 
eluate (Breeman et al., 2005, Zhernosekov et al., 2007, Asti et al., 2008, de Blois et 
al., 2011, Boschi et al., 2013). In our studies, a small volume of 68Ga-eluate (0.5 
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mL) was used. Due to the low eluate volume used, the contents of 68Ge and 
metallic impurities are reduced. (Zhernosekov et al., 2007)  
In Subproject I, HEPES buffer was used in the reaction mixture for 
radiolabeling nonGMP-grade [68Ga]Ga-DOTA-Siglec-9. HEPES has been 
reported, along with NaOAc and sodium succinate, to be the most favorable buffer 
for 68Ga-labeling (Bauwens et al., 2010). Our results revealed that HEPES 
dissolved completely in the 68Ga-eluate and the pH of the reaction mixture was 
optimal for radiolabeling DOTA-Siglec-9 peptide. Virtanen and co-workers have 
earlier used HEPES for radiolabeling [68Ga]Ga-DOTA-Siglec-9. (Ahtinen et al., 
2014, Virtanen et al., 2015)  
One disadvantage of HEPES is that, at the moment, it is not allowed for human 
use. Ph. Eur. defines it as an impurity and sets a limit for HEPES in the final 68Ga-
labeled product (Ph. Eur., 2013, Pfaff et al., 2018). However, Theodore and co-
workers have proved that HEPES has no deleterious effects even when 
administered daily in high doses to cancer patients over a period of 10 weeks 
(Theodore et al., 1997). As regards the automated synthesis protocol, SPE 
purification is considered to remove HEPES completely during the purification 
process (Pohle et al., 2012, Pfaff et al., 2018). In Subproject I, nonGMP-grade 
[68Ga]Ga-DOTA-Siglec-9 was radiolabeled for preclinical experiments. Therefore, 
use of HEPES in the radiolabeling procedure was possible. The amount of HEPES 
in the final product was not determined. 
In Subproject III, NaOAc buffer was used in the reaction mixture for 
radiolabeling nonGMP-grade 3′-[68Ga]Ga-NOTA-anti-microRNA-21. Unlike 
HEPES, NaOAc is allowed for human use. Previously, Mäkilä and co-workers 
have used NaOAc successfully for radiolabeling oligoribonucleotides (Mäkilä et 
al., 2014). In Subproject III, nonGMP-grade 3′-[68Ga]Ga-NOTA-anti-microRNA-
21 was radiolabeled for preclinical studies, but it is assumed that these 
radiolabeling conditions can be used as such or slightly modified for human studies 
as well.  
In Subproject III, reaction time for radiolabeling nonGMP-grade 3′-[68Ga]Ga-
NOTA-anti-microRNA-21 was 10 minutes. Mäkilä and co-workers have 
previously used a similar reaction time (Mäkilä et al., 2014). In Subproject I, 
reaction time for radiolabeling nonGMP-grade [68Ga]Ga-DOTA-Siglec-9 was 15 
minutes. This kind of a reaction time has also been used earlier (Virtanen et al., 
2015). We performed some tests with nonGMP-grade [68Ga]Ga-DOTA-Siglec-9 
using a decreased temperature (80°C or 90°C) and prolonged reaction time 
(approximately 17 minutes). However, we observed that non-chelated 68Ga 
remained in the reaction mixture even after the extended reaction time. Minor 
modifications to the reaction time have no significant impact on the overall yield. 
The influence of the small changes to the temperature was also supposed to be 
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insignificant. Several reported 68Ga-radiolabeling experiments have been 
conducted at a temperature exceeding 50°C. Tsionou and co-workers have 
concluded that, for the majority of the chelators, heating the reaction does not 
significantly increase RCY. They have also concluded that DOTA chelator is an 
exception, meaning that heating and low pH conditions are favourable in the case 
of DOTA. (Tsionou et al., 2017) 
DOTA- and NOTA-chelators require a relatively long reaction time at a high 
temperature in order to provide a high RCY. This is because of the slow kinetics of 
these chelate reactions. Therefore, decreasing the temperature may result in a lower 
RCY. However, peptides can be sensitive to harsh conditions like high 
temperature. Thus, decrease of the temperature can be necessary to obtain desirable 
RCY. 
In Subproject III, our conclusion was that hybridization of the alendronate 
moiety (5′-alendronate-conjugated microRNA-21, none, 1, 2 or 4 equivalents) has 
to be carried out after the 68Ga-chelation of 3′-NOTA-anti-microRNA-21. We had 
problems in performing the tests for producing 68Ga-labeled NOTA-chelated 
bis(phosphonate) conjugate of oligoribonucleotide. Several HPLC -analyses 
demonstrated that most of the radioactivity in the reaction mixture after the 
radiolabeling was free 68Ga. After the tested and modified radiolabeling conditions 
including, for example, prolonged reaction time, it was established that successful 
68Ga-labeling only occurred in the absence of 5′-alendronate-conjugated 
microRNA-21. Most likely, this is because of a plausible interaction between the 
bis(phosphonate) and NOTA-chelate which is able to interfere with 68Ga-chelation. 
Similar problems have been reported previously (Holub et al., 2015).  
[68Ga]Ga-DOTA-Siglec-9 peptide contains DOTA chelator. DOTA is a widely 
used chelator, mainly because of its exceptional in vivo stability, commercial 
availability and well studied coordination chemistry (Price and Orvig, 2014, Gijs et 
al., 2016). Previously, researchers in Turku PET Centre have studied Siglec-9 
containing DOTA and its potential as a PET tracer has been proven (Aalto et al., 
2011, Ahtinen et al., 2014, Virtanen et al., 2015, Silvola et al., 2016, Virtanen et 
al., 2017).  
Researchers in Turku PET Centre have jointly with collaborative parties 
studied NOTA-chelated oligonucleotides previously (Kiviniemi et al., 2012, 
Mäkilä et al., 2014). Kiviniemi and co-workers have successfully labeled 3′-NOTA 
and 3′-DOTA conjugated oligonucleotides with 68Ga (Kiviniemi et al., 2012). In 
Subproject III, 68Ga-labeled oligoribonucleotide contains NOTA chelator. NOTA 
has ideal radiolabeling properties and stability with 68Ga for diagnostic applications 
because its Ga(III) complex is thermodynamically more stable than that of DOTA 
(Price and Orvig, 2014, Gijs et al., 2016). However, thermodynamic stability is not 
critical here, meaning that DOTA chelator could also have been coupled to 
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oligoribonucleotide. When radiolabeling DOTA chelators, reaction solutions are 
heated since the purpose is to overcome substantial kinetic barriers. Radiolabeling 
of NOTA can be performed under mild conditions and at r.t. (Price and Orvig, 
2014, Gijs et al., 2016). Thus, the kinetic barriers to Ga3+ complexation are likely 
to be lower for NOTA than DOTA. Peptides like Siglec-9 can be sensitive to harsh 
conditions. For example, disruption of bonds can be seen. Accordingly, NOTA 
chelator coupled to Siglec-9 peptide could be even favored when compared with 
DOTA. (Tsionou et al., 2017)  
In Subproject III, three slightly different gradients were tested for the study of 
plasma protein binding and stability of 68Ga-labeled oligoribonucleotide. During 
the project, the gradient of solvent A (50 mM NH4OAc) was modified in order to 
obtain at sharper main peak. After the tested modifications, it was concluded that 
the original gradient (gradient 1) gave the sharpest main peak. Radioisotope 68Ga is 
a short-lived isotope (t½ = 68 minutes). This means that all the steps during the 
radiolabeling process (starting from the elution of 68Ge/68Ga generator until the 
68Ga-labeled final product is ready for injection) have to be optimized. It is useful 
that the gradient used for QC analysis of the 68Ga-labeled PET 
radiopharmaceuticals is optimized. In Subproject III, the duration of the gradient 
used for the QC analysis of nonGMP-grade 3′-[68Ga]Ga-NOTA-anti-microRNA-21 
was 17 minutes, in addition to washing with H3PO4 for 8 minutes. Optimizing the 
gradient duration by shortening it would be justified in the future.   
6.1.2 Acetone-based method and 68Ga-radiolabeling 
The purpose of Subproject II was to develop a production method for 
radiopharmaceutical [68Ga]Ga-DOTA-Siglec-9 in compliance with GMP. To our 
knowledge, Subproject II was the first study to represent a protocol for generating 
GMP-grade [68Ga]Ga-DOTA-Siglec-9, the first radiopharmaceutical for PET 
imaging of VAP-1 protein. 
A sticking problem was observed during the development work of GMP-grade 
[68Ga]Ga-DOTA-Siglec-9. During the development process, we concluded that 
although it is not large, the DOTA-Siglec-9 peptide is sensitive to radiolabeling 
conditions, for example, the combination of relatively high reaction temperature 
and high salt content. In order to solve the problem, we applied an acetone-based 
method for producing GMP-grade [68Ga]Ga-DOTA-Siglec-9 with a lower 
temperature, shorter reaction time, decreased concentration of NaOAc buffer and 
reduced concentration of NaCl. We concluded that introducing the acetone-based 
method solved the problems related to low RCY and sticking problem of the HPLC 
column. 
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One purpose of the development process was to establish milder reaction 
conditions. In order to reduce the salt content of the reaction mixture and the 
temperature of the radiolabeling reactions without compromising the potential 
RCY, we decided to test radiosynthesis with an acetone-based method. Acetone-
based method has been proven to deliver 68Ga-labeled compounds in high RCP and 
molar activity (Mueller et al., 2012). A cationic based post-processing method has 
been successfully applied to different types of radiolabeling precursors and it 
provides highly reproducible radiolabeling yields (Seemann et al., 2015). It has 
become more popular as opposed to the fractionated method (Prince et al., 2018). 
Purification of 68Ga-eluate using an acetone-based method has been described 
previously (Zhernosekov et al., 2007) and the acetone-based method is widely used 
for radiolabeling DOTA-conjugated peptides. (Poeppel et al., 2011, Schultz et al., 
2013, Wild et al., 2013, Ghai et al., 2018) 
However, acetone has its limitations. The acetone-HCl-based solution may 
contain breakdown impurities like mesityloxide and 4-methyl-3-penten-2-on which 
can be detected in the final products. Acetone is classified as Class 3 solvent, in 
other words, a solvent with low toxic potential, and its amount in medicinal 
products has to be measured. Determination of residual acetone level requires extra 
steps in the QC process. It calls for intensified production efforts for technical staff 
(Mueller et al., 2012) as well as maintenance and purchase of GC equipment. 
Acetone has to be eliminated from the final formulation. The boiling point of 
acetone is low (56°C). Thus, it is possible to remove acetone by heating up the 
reaction vial. During the development process of GMP-grade [68Ga]Ga-DOTA-
Siglec-9, we observed that acetone evaporated gradually into the waste vial via 
vent tubing.  
Development work of GMP-grade [68Ga]Ga-DOTA-Siglec-9 was done taking 
into account the requirements set for GMP production. An automated synthesis 
device (initially Modular-Lab Standard, later on Modular-Lab PharmTracer) was 
used. Modular-Lab Standard is more like a manual system than Modular-Lab 
PharmTracer. It contains re-usable plastic tubes and vials made of glass. Modular-
Lab PharmTracer is a cassette-based system using disposable cassettes. The trend 
towards using fully automated systems has been increasing in the recent years to 
overcome the intrinsic limitations of manual or semi-automated systems, and pre-
loaded cassette-based modules have represented improvement in terms of 
compliance and safety. (Boschi et al., 2013) 
Discussion 
 95 
6.2 In vivo imaging and ex vivo biodistribution 
experiments 
The hypothesis that an appropriate conjugation with bis(phosphonate) would 
increase the bone accumulation of a potential oligoribonucleotide in vivo was 
proven in Subproject III. The excess (2 or 4 equivalents versus 1 equivalent) of 5′-
alendronate-conjugated microRNA-21 used for the hybridization did not show 
marked variation in the accumulation or distribution kinetics. Accordingly, it was 
argued that an incomplete hybridization did not interfere with the desired systemic 
bone-targeted delivery and neither did the excess of 5′-alendronate-conjugated 
microRNA-21 do so. In previous studies, a high bone uptake potential, 
accumulation in bone and a high bone to blood ratio of 67/68Ga-labeled DOTA- and 
NOTA-bis(phosphonates) using PET imaging have been proven (Ogawa et al., 
2011, Suzuki et al., 2011, Meckel et al., 2013, Holub et al., 2015). 
It is possible that this bone accumulation proof of concept will find further 
applications in targeting of double-helical RNAs to bone-forming surfaces. 
However, several important issues must be resolved prior to plausible therapeutic 
applicability. In the future, independent studies considering the bone cell 
internalization of the single strand RNA or the double helical RNA are required. 
Another important issue is the sequence complementarity. The stable double helix 
facilitates the systemic bone matrix-targeted delivery. The action of the potential 
therapeutically active single strand (anti-microRNA-21) could be hampered. In the 
future, the bone accumulation should be further enhanced. It can be assumed that 
multiple bis(phosphonate) units may provide the desired enhancement. 
6.3 Plasma protein binding and stability in vivo and 
in vitro experiments 
In Subproject I, the purpose was to set up an experiment to look at the species-
specific variation of the [68Ga]Ga-DOTA-Siglec-9 in vitro behavior in plasma. It is 
highly important to understand the plasma protein binding of potential PET 
radiopharmaceuticals. This is because binding has great implications for the 
kinetics of PET radiopharmaceuticals. Plasma protein binding in human plasma 
was part of the experiment. It is useful to study how [68Ga]Ga-DOTA-Siglec-9 
behaves in human plasma in vitro. In the future, these results can be compared with 
the in vivo results obtained. We concluded that the binding efficiency cannot be 
directly compared because the plasma concentrations of soluble VAP-1 and the 
sequence of VAP-1 vary greatly between different species. It is pointed out that 
any in vitro or animal data should be used with caution in assessing the properties 
of [68Ga]Ga-DOTA-Siglec-9 for human use. The plasma protein binding 
experiment was justified because it is known that [68Ga]Ga-DOTA-Siglec-9 binds 
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to plasma proteins when injected into the bloodstream (Retamal et al., 2016). High 
plasma protein binding reduces glomerular filtration and increases bloodstream 
half-life.  
It is essential to understand the stability of potential PET 
radiopharmaceuticals. It is necessary to determine that PET radiopharmaceuticals 
will be stable enough in the organism so that they can be used for PET imaging. 
According to our results, the stability of [68Ga]Ga-DOTA-Siglec-9 varied greatly 
between species. Differences in stability between species are possibly due to the 
differences in metabolism between species, for example how fast [68Ga]Ga-DOTA-
Siglec-9 is metabolized in blood. It is assumed that [68Ga]Ga-DOTA-Siglec-9 may 
bind to different plasma proteins depending on species and this could explain the 
differences between species.  
For example, there was a huge difference in stability between pig’s plasma and 
rabbit’s plasma. We observed that the decrease of the stability was moderate for 
human plasma. Virtanen and co-workers have reported previously that, after 
incubation at 37°C for 60 minutes in rabbit’s plasma, the radioactivity associated 
with intact [68Ga]Ga-DOTA-Siglec-9 was 94 ± 1.0% (n = 2) (Virtanen et al., 2015). 
In comparison, our results were different. We observed that, at the same time point, 
approximately 60% of [68Ga]Ga-DOTA-Siglec-9 was intact (n=3). The 
experimental setup was quite similar in both studies. Differences between the 
results can be explained by, for example, differences between individual animals. 
Larger experimental materials would be justified in the future. 
In Subproject III, one aim was to study plasma protein binding and stability of 
both nonGMP-grade 3′-[68Ga]Ga-NOTA-anti-microRNA-21 and 68Ga-labeled 
double helix structure. We concluded, that according to the radio-HPLC analysis, 
the in vitro plasma protein binding of nonGMP-grade 3′-[68Ga]Ga-NOTA-anti-
microRNA-21 alone was clearly lower as compared with the 68Ga-labeled double 
helix structure. The reason for this difference of plasma protein bindings could be 
either that single-stranded oligonucleotide is bound to plasma protein more weakly 
in this context or that the bis(phosphonate) conjugated to double helix affects the 
plasma protein binding by increasing it. 
We observed that the 68Ga-labeled double helix structure was quite stable at r.t. 
(≥90%) and more stable when compared with nonGMP-grade 3′-[68Ga]Ga-NOTA-
anti-microRNA-21 alone. The results obtained by Ogawa and co-workers and 
Suzuki and co-workers support our observation that 68Ga-labeled bis(phosphonate) 
complexes are stable in vitro (Ogawa et al., 2011, Suzuki et al., 2011). 
In Subproject III, we found that 68Ga-labeled double helix was more stable in 
rat’s plasma in vivo when compared with nonGMP-grade 3′-[68Ga]Ga-NOTA-anti-
microRNA-21 alone. Our results are in agreement with previous studies previous 
studies reporting that the rates of in vivo degradation of double helical 
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oligoribonucleotides are usually lower than those of the corresponding single 
strands (Braasch et al., 2004, Roivainen et al., 2004, Viel et al., 2008, Lendvai et 
al., 2009, Rettig and Behlke, 2012). 
6.4 Future considerations 
The increasing clinical demand of 68Ga-labeled tracers has prompted the need for 
extensive automation of the production process for 68Ga-radiopharmaceuticals. 
Nowadays, various automation strategies tailored to different needs are available 
and several commercial automatic devices have been developed. All of the 
automated systems approved for marketing provide a safe and effective synthesis 
of 68Ga-radiolabeled tracers and ensure that the safety and quality of 68Ga-
radiopharmaceuticals is adequate for their intended use. These technologies have 
implemented different pre-purification approaches. They lead to an increased 
radionuclidic purity, RCP and high molar activity of the final preparation. High and 
reproducible throughput, robustness of the synthesis and radioprotection aspects 
have led to a great diffusion of automated technology in cGMP compliant 
environments. (Boschi et al., 2013)  
68Ge/68Ga generators and cyclotrons are used for the production of 68Ga. 
Cyclotron-produced 68Ga is proven to be, at least, as high-quality as generator-
produced 68Ga for the production of 68Ga-labeled tracers. A cyclotron is an 
economical alternative to 68Ge/68Ga generators and it shows potential for large 
scale production of 68Ga. (Pandey et al., 2014, Lin et al., 2018, Riga et al., 2018) 
68Ga has several benefits. The labeling synthesis is amenable to kit type 
preparation and automation. 68Ga provides sufficient levels of radioactivity for high 
quality images and short scanning time, thus facilitating fast patient examination. 
However, it should be pointed out that this performance depends on the in vivo 
kinetics of the imaging probe. 68Ga also makes possible to minimize the radiation 
dose to the patient and personnel and allows fast discharge of the patient. 
Moreover, repetitive examinations within the same day are possible. (Velikyan et 
al., 2010, Velikyan, 2014) 
It has  been proposed that the future development of 68Ga-radiopharmaceuticals 
must be put in the context of several aspects, such as production and availability of 
68Ga, automation of the radiopharmaceutical production, PET radiopharmaceutical 
regulations as well as radiopharmaceutical chemistry advances, identification of 
new biomarkers, targets and corresponding ligands, role of PET in nuclear 
medicine, unmet medical needs and progress of PET technologies and image 
analysis methodologies for improved quantitation accuracy. (Velikyan, 2014) 
In Subproject III, the bone accumulation of a potential small-interfering anti-
microRNA-21/microRNA-21 double helix was shown to be increased by an 
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appropriate conjugation with bis(phosphonate). This was done using 68Ga-labeled 
NOTA-chelated oligoribonucleotide and PET imaging. 68Ga-labeling and QC of 
NOTA-chelated oligoribonucleotide were studied. In the future, it is recommended 
to optimize the radiolabeling protocol for oligoribonucleotide radiolabeling 
conditions and amount of precursor. Additional tests to collect more data and study 
the potential of this PET tracer in animal experiments are recommended. It is 
desirable that its potential as a PET tracer in human studies could be established in 
the future.  
[68Ga]Ga-DOTA-Siglec-9 has been shown to be a promising PET tracer for 
imaging of inflammation in animal studies. The intention is to use this novel PET 
radiopharmaceutical in human studies and investigate its potential for clinical use 
in the future. The synthesis protocol for GMP-grade [68Ga]Ga-DOTA-Siglec-9 
developed here has made the first-in-human studies possible. In the future, it is 
possible that [68Ga]Ga-DOTA-Siglec-9 can be utilized as a PET 
radiopharmaceutical for imaging of inflammation in routine clinical production. 
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7 Conclusions 
Problems encountered in the PET radiopharmaceutical production of GMP-grade 
[68Ga]Ga-DOTA-Siglec-9 were solved. In vitro experiments concerning the plasma 
protein binding and stability of nonGMP-grade [68Ga]Ga-DOTA-Siglec-9 were 
performed and compared among different species. In addition, bis(phosphonate)-
induced bone accumulation of nonGMP-grade 68Ga-labeled NOTA-chelated 
bis(phosphonate)-conjugated oligoribonucleotide and its biodistribution were 
studied. The main conclusions were: 
1. GMP-grade [68Ga]Ga-DOTA-Siglec-9 is produced efficiently and 
rapidly using a fully automated acetone-based method. The GMP-grade 
tracer is suitable for human use. 
2. The stability of nonGMP-grade [68Ga]Ga-DOTA-Siglec-9 in plasma in 
vitro depends heavily on which species the plasma comes from. Plasma 
protein binding of nonGMP-grade [68Ga]Ga-DOTA-Siglec-9 in vitro 
shows species-specific differences. Fast initial binding is observed in all 
examined species. 
3. NonGMP-grade 3′-[68Ga]Ga-NOTA-anti-microRNA-21 is produced 
successfully using the fractionated method. 68Ga-radiolabeled NOTA-
chelated bis(phosphonate)-conjugated anti-microRNA-21/microRNA-
21 double helix forms successfully at r.t. within 10 minutes. 
4. Bis(phosphonate)-induced bone accumulation of the double helical 
RNA in healthy rats is verified. 68Ga-radiolabeled double helix structure 
is more stable at r.t. in vitro in comparison with nonGMP-grade 3′-
[68Ga]Ga-NOTA-anti-microRNA-21 alone. NonGMP-grade 3′-
[68Ga]Ga-NOTA-anti-microRNA-21 alone is more stable in rat’s 
plasma in vitro as compared with 68Ga-radiolabeled double helix 
structure. 
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Synthesis protocols for producing GMP-grade [68Ga]Ga-DOTA-Siglec-9 and 
nonGMP-grade 3′-[68Ga]Ga-NOTA-anti-microRNA-21 were developed and used 
successfully. The radiolabeling protocol for nonGMP-grade 3′-[68Ga]Ga-NOTA-
anti-microRNA-21 needs further optimization. In vitro, in vivo and ex vivo 
experiments as well as PET imaging were used for studying the stability, plasma 
protein binding and bone accumulation of the 68Ga-radiolabeled tracers. However, 
a larger number of experimental animals should be used in the future. 
Bis(phosphonate)-induced bone accumulation can be utilized when developing 
medicinal treatments for diseases involved micro-RNA-21 like osteoporosis and 
osteosarcoma.  
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